Protocol (a)  I8K-JE-JPDB  
 
A Single - and Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and 
Pharmacodynamics of LY3337641 in Japanese and Caucasian Healthy Subjects 
 
[STUDY_ID_REMOVED]  
Approval Date: 16- Mar-2017 
 
 
 
I8K - JE- JPDB(a )C l in ica l  Pha rmaco logy  P ro toco l Page  1
LY3337641P ro toco l  I8K - JE- JPDB
A  S ing le-and  Mu l t ip le- Dose  S tudy to  Eva lua te  the  Sa fe ty ,  
To le rab i l i ty,  Pha rmacok ine t ics ,  and  Pha rmacody nam ics  o f  
LY3337641  in  Japanese  and  Caucas ian  Hea l thy Sub jec ts
Con f iden t ia l  In fo rma t ion
The  in fo rma t ion  con ta ined  in  th is  p ro toco l  is  con f iden t ia l  and  is  in tended  fo r  the  use  o f  
c l in ica l  inves t iga to rs .   I t  is  the  p rope r ty  o f  E l i  L i l ly  and  Company  o r  i ts  subs id ia r ies  and  
shou ld  no t  be  cop ied  by  o r  d is t r ibu ted  to  pe rsons  no t  invo lved  in  the  c l in ica l  inves t iga t ion  o f  
LY3337641,  un less  such  pe rsons  a re  bound  by  a  con f iden t ia l i ty  ag reemen t  w i th  E l i  L i l ly  
and  Company  o r  i ts  subs id ia r ies .
No te  to  Regu la to ry  Au tho r i t ies :  Th is  documen t  may  con ta in  p ro tec ted  pe rsona l  da ta  
and /o r  comme rc ia l ly  con f iden t ia l  in fo rma t ion  exemp t  f rom  pub l ic  d isc losu re .   E l i  L i l ly  and  
Company  reques ts  consu l ta t ion  rega rd ing  re lease / redac t ion  p r io r  to  any  pub l ic  re lease .   In  
the  Un i ted  S ta tes ,  th is  documen t  is  sub jec t  to  F reedom  o f  In fo rma t ion  Ac t  (FO IA )  
Exemp t ion  4  and  may  no t  be  rep roduced  o r  o the rw ise  d issem ina ted  w i thou t  the  w r i t ten  
app rova l  o f  E l i  L i l ly  and  Company  o r  i ts  subs id ia r ies.
App ro va l  Da te :  16 -Ma r -2017  GMTLY3337641
E l i  L i l ly  Japan  K .K .
Kobe  Hyogo  Japan
C l in i ca l  Pha rma co log y  P ro to co l  E le c t ron i ca l l y  S igned  and  App ro ved  b y  L i l l y:
24De cembe r  2016
Amendmen t  (a)  E lec t ron ica l ly  S igned  and  App roved  by  L i l ly
on  app rova l  da te  p rov ided  be low.
I8K-JE-JPDB(a) Clinical Pharmacology Protocol Page 2
LY3337641Table of Contents
A Single -and Multiple -Dose Study  to Evaluate the Safety , 
Tolerability , Pharmacokinetics, and Pharmacody namics of 
LY3337641 in Japanese and Caucasian Healthy  Subjects
Section Page
Protocol  I8K-JE-JPDB A Single -and Mul tiple-Dose Study  to Eval uate the 
Safety, Tolerabili ty, Pharm acokinetics, and Ph armacodynamics of 
LY3337641 in Japanese and Caucasian Healt hy Subjects .................................................... 1
Table of Contents ........................................................................................................................ 2
1. Protocol  Synopsi s................................................................................................................ 8
2. Schedule of Act ivities....................................................................................................... 10
3. Introduction ...................................................................................................................... 15
3.1. Study  Rati onale ............................................................................................................ 15
3.2. Background .................................................................................................................. 15
3.3. Benefit /Risk Assessment .............................................................................................. 16
4. Object ives and Endpo ints.................................................................................................. 17
5. Study  Design ..................................................................................................................... 18
5.1. Overall Design ............................................................................................................. 18
5.2. Number of Participants .................................................................................................19
5.3. End of Study  Definit ion............................................................................................... 19
5.4. Scientific Rationale for Study  Design ........................................................................... 19
5.5. Justification for Dose ................................................................................................... 20
6. Study  Popul ation............................................................................................................... 21
6.1. Inclusio n Cri teria.......................................................................................................... 21
6.2. Exclusio n Cri teria........................................................................................................ 22
6.3. Lifest yle and/or Dietary Requirements ......................................................................... 24
6.3.1. Meals and Dietary  Restri ctions............................................................................. 24
6.3.2. Caffeine, Alcoho l, and Tobacco ........................................................................... 25
6.3.3. Activity................................................................................................................ 25
6.4. Screen Failures ............................................................................................................. 25
7. Treat ment .......................................................................................................................... 26
7.1. Treatment Administered ............................................................................................... 26
7.1.1. Packaging and Labeling ....................................................................................... 27
7.2. Method of Treatment Assignment ................................................................................ 27
7.2.1. Selection and Timing o f Doses ............................................................................. 27
7.3. Blinding ....................................................................................................................... 27
I8K-JE-JPDB(a) Clinical Pharmacology Protocol Page 3
LY33376417.4. Dose Modi fication........................................................................................................ 28
7.4.1. Dose Escal ation.................................................................................................... 28
7.5. Preparati on/Handling/Storage/Accountabilit y............................................................... 29
7.6. Treatment Compliance .................................................................................................29
7.7. Concomitant Therapy ................................................................................................... 29
7.8. Treatment after the End of the Study ............................................................................ 29
8. Discontinuati on Cri teria .................................................................................................... 30
8.1. Discontinuati on from Study  Treatm ent......................................................................... 30
8.1.1. Discontinuati on of  Inadvertent ly Enrolled Subjects .............................................. 30
8.2. Discontinuati on from the Study .................................................................................... 31
8.3. Subjects Lost to Follow -up........................................................................................... 31
9. Study  Assessments and Procedures ................................................................................... 32
9.1. Efficacy Assessments ................................................................................................... 32
9.2. Adverse Events ............................................................................................................ 32
9.2.1. Serious Adverse Events ........................................................................................ 33
9.2.1.1. Suspected Unexpected Serious Adverse React ions.......................................... 33
9.2.2. Com plaint Handling ............................................................................................. 33
9.3. Treatment of Overdose .................................................................................................34
9.4. Safety........................................................................................................................... 34
9.4.1. Laboratory  Tests .................................................................................................. 34
9.4.2. Vital Signs ........................................................................................................... 34
9.4.3. Electrocardi ogram s.............................................................................................. 34
9.4.4. Other Tests ........................................................................................................... 35
9.4.4.1. Assessment and Management of Subjects Developing a 
Rash ............................................................................................................... 35
9.4.5. Safety Moni toring ................................................................................................ 36
9.5. Pharmacokinet ics......................................................................................................... 36
9.5.1. Bioanalysis ........................................................................................................... 36
9.6. Pharm acodynamics ...................................................................................................... 37
9.7. Genet ics....................................................................................................................... 37
9.8. Biomarkers ................................................................................................................... 37
9.9. Heal th Economics ........................................................................................................ 38
10. Statistical Considerations and Data Analysis ..................................................................... 39
10.1. Sample Si ze Determinat ion.......................................................................................... 39
10.2. Popul ations for Analyses .............................................................................................. 39
10.2.1. Study  Parti cipant Disposit ion............................................................................... 39
10.2.2. Study  Parti cipant Characterist ics.......................................................................... 39
10.3. Statistical Analyses ...................................................................................................... 39
I8K-JE-JPDB(a) Clinical Pharmacology Protocol Page 4
LY333764110.3.1. Safety Analyses .................................................................................................... 39
10.3.1.1. Clinical Evaluation of Safet y.......................................................................... 39
10.3.1.2. Statistical Evaluat ion of Safet y....................................................................... 40
10.3.2. Pharmacokinet ic Analyses .................................................................................... 40
10.3.2.1. Pharmacokinet ic Parameter Estimat ion........................................................... 40
10.3.2.2. Pharmacokinet ic Statistical Inference ............................................................. 40
10.3.3. Pharmacodynamic Analyses ................................................................................. 40
10.3.4. Pharmacokinet ic/Pharmacodynamic Analyses ...................................................... 41
10.3.5. Interim Analyses .................................................................................................. 41
11. References ........................................................................................................................ 42
I8K-JE-JPDB(a) Clinical Pharmacology Protocol Page 5
LY3337641List of Tables
Table Page
Table JPDB.1. Object ives and Endpo ints....................................................................... 17
Table JPDB.2. Treatment Administered ......................................................................... 26
Table JPDB .3. Amendment Summary for Protocol I8K- JE-JPDB Amendment( a).......... 56
I8K-JE-JPDB(a) Clinical Pharmacology Protocol Page 6
LY3337641List of Figures
Figure Page
Figure JPDB.1. Illustrati on of  study  design for Protocol I8K -JE-JPDB. ........................... 19
I8K-JE-JPDB(a) Clinical Pharmacology Protocol Page 7
LY3337641List of Appendices
Appendix Page
Appendix 1. Abbreviat ions and Definit ions................................................................ 43
Appendix 2. Clinical Laboratory  Tests ........................................................................ 47
Appendix 3. Study  Governance, Regulatory  and Ethi cal Considerati ons..................... 48
Appendix 4. Hepati c Moni toring Tests for Treatme nt-Emergent Abnormalit y............ 51
Appendix 5. Blood Sam pling Summary ...................................................................... 52
Appendix 6. Protocol  I8K-JE-JPDB Blinding/Unblinding Plan ................................... 53
Appendix 7. Protocol  Amendment I8K -JE-JPDB(a) Summary
A Single -and Mul tiple-Dose Study  to Eval uate the Safet y, 
Tolerabilit y, Pharmacokinet ics, and Pharmacodynamics o f 
LY3337641 in Japanese and Caucasian Healt hy Subjects ....................... 55
I8K-JE-JPDB(a) Clinical Pharmacology Protocol Page 8
LY33376411.Protocol Synopsis
Title of Study:
A Single -and Multiple -Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics 
of LY3337641 in Japanese and Caucasian Healthy Subjects
Rationale: 
Study I8K -JE-JPDB (JPDB) is the first clinical evaluation of LY3337641 in Japanese subjects and is being 
conducted to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single -dose 
(SD) and multiple -dose (MD) administration of LY3337641 in healthy  Japanese and Caucasian subjects.  Findings 
from the study will be used to assess the safety and tolerability of LY3337641 in this study population including 
Japanese subjects , further characterize the PK pro perties of LY3337641 , and explore the PD effects of Bruton’s 
tyrosine kinase inhibition.  Such findings in Japanese subjects are essential for further clinical development in Japan 
for various indications.
Objectives/Endpoints:   
Objectives Endpoints
Primary
To explore the safety and tolerability of LY3337641 in 
healthy  Japanese and Caucasian subjects AEs and SAEs
Secondary
To estimate the PK parameters of single and multiple 
doses of LY3337641 following oral administration in 
healthy  Japanese and C aucasian subjectsCmaxand AUC
Abbreviations: AEs =adverse event s; AUC =area under the plasma concentration -time curve; C max=maximum 
drug concentration; PK =pharmacokinetic; SAEs =serious adverse event s.
Summary of Study Design:
Study J PDB is a single -site, subject -and investigator -blind, randomized, placebo -controlled, SDand MDstudy to 
assess the safety, tolerability, PK, and PD of LY3337641 in healthy  Japanese and Caucasian subjects.  
Treatment Arms and Duration:   
Screening may occur up to 28 days prior to the firstdose (Day 1) .  All cohorts will be randomized in a 3:1 ratio of 
LY3337641 to placebo.  Study JPDB will numerically compare LY3337641 (30 mg once daily in MD cohorts and 
5, 80, and160mg in SD cohorts) with placebo, when administered orally .  An  optional cohort may be included in 
the MD portion. 
The study drug is supplied as tablets containing 5 or 20 mg of LY3337641 with matching 
placebo tablets.  For the MD cohorts , 6 Japanese subjects and 3 Caucasian sub jects will receive LY3337641,
while2Japanese subjects and 1 Caucasian subject will receive placebo.  For the SD cohort s, 3Japanese subjects 
and3Caucasian subjects will receive LY3337641, while 1 Japanese subject and 1 Caucasian subject will 
receive placebo.   
In the MD cohort s, LY3337641 or placebo will be dosed on Days 1 through 15, and subjects will be followed for 
approximately 2 weeks .  In the SD cohort s, LY3337641 or placebo will be dosed on Day 1 ,and subjects will be 
followed for approximately 2weeks. 
I8K-JE-JPDB(a) Clinical Pharmacology Protocol Page 9
LY3337641Number of Subjects:
Up to 60subjects may be enrolled so that approximately 36to 48subjects complete the study.  
Statistical Analysis:
PK analyses will be conducted for all subjects who receive at least 1 dose of LY3337641 and have evaluable PK 
data.  PD analyses will be conducted on the full analysis set ,which includes all data from all subjects receiving at 
least 1 dose of LY3337641 or placebo.  Safety analyses will be conducted for all randomized subjects who receive at 
least 1 d ose of LY3337641 or placebo and have at least 1postdose safety assessment , regardless of whether they 
have completed all protocol requirements.  For QT interv al, all subjects with at least 1post
dose QT interval 
measurement will be included in the analysis. Summary statistics, data tabulations, and data graphs will be provided 
and may be separated by race (Japanese and Caucasian) as appropriate.
Safety:  All adverse events will be listed, and if the frequency of events allows, safety data will be summarized using 
descriptive methodology.  The incidence of symptoms for each treatment will be presented by severity and by 
association with the investigational product as perceived by the investigator.  Sym ptoms reported to occur prior to 
enrollment will be distinguished from those reported as new or increased in severity during the study.  Each 
symptom will be classified by the most suitable term from the medical regulatory dictionary.   The number of 
invest igatio nal-product –related serious adverse events will be reported.  Laboratory parameters, vital signs, and 
electrocardiogram parameters will be summarized using standard descriptive statistics.
PKAnaly sis:  PK parameter estimates for LY3337641 will be ca lculated using standard noncompartmental methods 
of analy sis.  In the SD cohort s, the primary parameters for analysis will be maximum drug concentration (C max), 
area under the concentration versus time curve from zero to infinity (AUC 0-∞),and area under t he concentration 
versus time curve from 0 to 24 hours(AUC 0-24) of LY3337641.  In the MD cohort s, the primary parameters to be 
calculated will include C max (or Cmax during a dosing interval at steady state [Cmax,ss ])and area under the 
concentration versus time curve during the dosing interval (AUC 0-τ) of LY3337641 after the first and last dose of 
investigational product .  Other noncompartmental parameters, such as half -life, apparent clearance, apparent volume 
of distribution ,and accumulation ratio (MD pe riod only ),may be reported .  
PD Analy sis:  Bruton’s tyrosine kinase occupancy will be listed and summarized using standard 
descriptive statistics.  
I8K-JE-JPDB(a) Clinical Pharmacology Protocol Page 10
LY33376412.Schedule of A ctivities
I8K-JE-JPDB(a) Clinical Pharmacology Protoco l Page 11
LY3337641Study Schedule Protocol I8K -JE-JPDB (Cohorts 1 and 5)
Visit Screening Treatment Period a Follow -Upa
Study Day ≤28 days -2 -1 1 b 2 4 8 11 15 16 17 19 22 25 29/
EoS
Inpatient stayat CRU
Informed consent X
Review eligibility X X
Randomization X
IPadministration c X X X X X X
Complete medical history X
Review preexisting 
conditio ns/AE sdX X X X X X X X X X X X X X X
Review concomitant 
medication sdX X X X X X X X X X X X X X X
Complete p hysical 
examinationX X X
Symptom -directed 
physical examination dX X X X X X X X X X X X
Body weight and height e X X X X
Vital signs (pulse rate, 
blood pressure, body 
temperature) fX 0 0, 1, 2, 4, 12 24i 0 0 0 0, 1, 2, 4, 12 24 48 X
12-Lead ECG g X -1, -0.5, 0, 0.5, 
1, 2, 3, 4, 6, 1224i 0 0 0 0, 0.5, 1, 2, 3, 
4, 6, 1224 48 X
Chest x- ray (posterior, 
anterior ,and lateral)X
Clinical laboratory 
measures (serum 
chemistry , hematology, 
urinaly sis)X 0 24 i 0 48 X
HBcAb, HBsAg, HCV ,
and HIV testsX
Serum pregnancy  testh X
Urine pregnancy  testh X 0 0 X
I8K-JE-JPDB (a)Clinical Pharmacology Protoco l Page 12
LY3337641Visit Screening Treatment Period a Follow -Upa
Study Day ≤28 days -2 -1 1 b 2 4 8 11 15 16 17 19 22 25 29/
EoS
FSH h X
Drug and alcohol screen X X
QuantiFERON ®-TB 
Gold PlusX
PK sampling: blood 0, 0.25, 0.5, 1, 
2, 3, 4, 6, 8, 10, 
1224i 0 0 0 0, 0.25, 0.5, 1, 
2, 3, 4, 6, 8, 
10, 1224, 36 48 X X X X
BTK occupancy 0, 1, 2, 4, 12 24 i 0 0, 1, 2, 4, 12 24 48 X X X X
Skin inspection d X 0, 12 24 i 0 0 0 0 X X X X X X
Non-PGx stored sample 0 0 24
PGx 0
Abbreviations :  AE s =adverse event s;BTK =Bruton’s tyrosine kinase ; CRU =clinical research unit; ECG =electrocardiogram; E oS=end of study ; 
FSH =follicle -stimulating hormone; HBcAb =hepatitis B core antibody; HBsAg =hepatitis B surface antigen; HCV =hepatitis C virus; HIV =human 
immunodeficiency virus; IP= investigational product; PGx =pharmacogenomics; PK=pharmacokinetic; TB =tuberculosis .
Note:  numbers are in hours in relatio n to dosing; 0=predose.
aAll planned procedures will be done predose unless the time is indicated.
bFor twice -daily  regimen, the time is based on the first dose .  The second dose should be administered after sample collection for the 12-hour time point .
cSubjects will be dosed ever yday from Day  1 through Day 15.  For twice -daily  regimen, only the morning dose will be administered on Day 15 .
dAssessment should be performed ever yday during the subject ’s stay at the CRU.
eHeight will be measured at screening only .  Body weight will be measured in the morning.
fRefer to Section 9.4.2 for instructions on vital signs.
gRefer to Section 9.4.3 for instructions on ECGs .  ECGs should be administered after subject has been resting in the supine position for approximate ly
5minute s.  On day s without dosing ,ECGs should be administered close to the Day 1 dosing time, whe npossible .  ECGs will be collected in triplicate except 
at the screening visit.
hAll female subjects of childbearing potential will undergo a serum pregnancy test at screening.  For women who are considered postmenopaus al, FSH should 
be drawn to confirm postmenopausal status as defined in inclusion criterion [1b] and exempt ionfromfurther pregnancy tests (urine) during the study .  
iThis 24 -hour sample is to be taken predose.
I8K-JE-JPDB (a)Clinical Pharmacology Protoco l Page 13
LY3337641Study Schedule Protocol I8K -JE-JPDB (Cohorts 2, 3, and 4)
Visit Screening Treatment Period a Follow -Upa
Study Day ≤28 days -2 -1 1 2 3 5 8 11 15/EoS
Inpatient stay at CRU
Informed consent X
Review eligibility X X
Randomization X
IPadministration X
Complete medical history X
Review preexisting 
conditio ns/AE sX X X X X X X X X X
Review concomitant 
medication sX X X X X X X X X X
Complete p hysical 
examinationX X X
Symptom -directed 
physical examinationX X X X X X X
Body weight and height b X X X X
Vital signs (pulse rate, 
blood pressure, body 
temperature) cX 0 0, 1, 2, 4, 12 24 48 X
12-Lead ECG d X -1, -0.5, 0, 0.5, 1, 2, 3, 
4, 6, 1224 48 X
Chest x -ray (posterior, 
anterior ,and lateral)X
Clinical laboratory 
measures (serum 
chemistry , hematology, 
urinaly sis)X 0 48 X
HBcAb, HBsAg, HCV ,
and HIV testsX
Serum pregnancy  teste X
Urine pregnancy  teste X X
FSH e X
I8K-JE-JPDB (a)Clinical Pharmacology Protoco l Page 14
LY3337641Visit Screening Treatment Period a Follow -Upa
Study Day ≤28 days -2 -1 1 2 3 5 8 11 15/EoS
Drug and alcohol screen X X
QuantiFERON ®-TB 
Gold PlusX
PK sampling: blood 0, 0.25, 0.5, 1, 2, 3, 4, 
6, 8, 10, 1224, 36 48 X X
BTK occupancy 0, 1, 2, 4, 12 24 48 X X
Skin inspection X 0, 12 X X X X X X
Non-PGx stored sample 0 X X
PGx 0
Abbreviations :  AE s =adverse event s;BTK =Bruton’s tyrosine kinase ; CRU =clinical research unit; ECG =electrocardiogram; E oS=end of study ; 
FSH =follicle -stimulating hormone; HBcAb =hepatitis B core antibody; HBsAg =hepatitis B surface antigen; HCV =hepatitis C virus; HIV =human 
immunodeficienc y virus; IP= investigational product; PGx =pharmacogenomics; PK=pharmacokinetic ;TB=tuberculosis .
Note:  numbers are in hours in relatio n to dosing; 0 = predose.
aAll planned procedures will be done predose unless the time is indicated.
bHeight will be measured at screening only .  Body weight will be measured in the morning.
cRefer to Section 9.4.2 for instructions on vital signs.
dRefer to Section 9.4.3 for instructions on ECGs .  ECGs should be administered after subject has been resting in the supine position for approximate ly
5minute s.  On day s without dosing ,ECGs should be administered close to the Day 1dosing time, whe npossible .  ECGs will be collected in triplicate except 
atthe screening visit.
eAll female subjects of childbearing potential will undergo a serum pregnancy test at screening.  For women who are considered postmenopausal, FSH should 
be drawn to confirm postmenopausal status as defined in inclusion criterion [1b] and exempt ion fromfurther pregnancy tests (urine) during the study .  
I8K - JE- JPDB(a )C l in ica l  Pha rmaco logy  P ro tocol Page  15
LY33376413 .In t roduc t ion
3 .1 .S tudy  Ra t iona le
S tudy I8K - JE - JPD B( JPDB )  i s  th e  f i r s t  c l i n i c a l  e v a l u a t i o n  o f  LY 3 3 3 7 6 4 1i n  J a p a n e s e  s u b j e c t s  
a n d  i s  b e i n g  c o n d u c t e d  t o  a s s e s s  t h e  s a f e t y , to l e r ab i l i ty ,  ph a rm a c o k i n e t i c s  (PK ) ,  a n d  
p h a rm a c o d y n am i c s  (PD )  o f  s i n g l e -d o s e(SD )a n d  m u l t i p l e - do s e(MD )  a dm i n i s t r a t i o no f  
LY3 3 3 7 6 4 1i n  h e a l th y  J a p a n e s e  a n d  C a u c a s i a n  s u b j e c t s .   F i n d i n g sf r o m  th e  s tudy  w i l l  b e  u s e d  
toa s s e s s  t h e  s a f e t y  and  to l e r ab i l i ty  o f  LY3337641  in  th i s  s tudy  popu l a t i o ni n c l u d i n g  J a p a n e s e
sub j e c t s ,  f u r th e r  c h a r a c t e r i z e  t h e  PK  p r o p e r t i e so f  L Y 3 3 3 7 6 4 1 ,  a n d  e x p l o r e  t h e  PD  e f f e c t s  o f  
B ru ton ’ s  tyro s in e  k in a s e  ( BTK)i n h i b i t i o n .   S u c h  f i n d i n g s  i n  J a p a n e s e  s u b j e c t s  a r ee s s e n t i a l  f o r  
f u r t h e r  c l i n i c a l  d e v e l o pm e n t  i n  J a p a n  f o r  v a r i o u s  i n d i c a t i o n s .   
3 .2 .Backg round
CC ILY 3 3 3 7 6 4 1  i s  a n  o r a l l y  a v a i l a b l e ,  i r r e v e r s i b l e  i n h i b i t o r  o f  BTK ,  a  m em b e r  o f  t h e  TEC  f am i l y  
o fcy top l a sm i c  ty ro s in e  k in a s e s .   BTK  is  a  k ey  s i gn a l ing  m o l e cu l e  in  th e  B - c e l l – r e c ep to r  and  
F c- r e c e p t o r  p a t hw a y s  a n d  a n  e s s e n t i a l  m ed i a to r  o fB -c e l l –a n d  m y e l o i d - c e l l – d ep end en t  
in f l amm a to ry  a r th r i t i s  (D i  P ao l o  e t  a l .  2 0 1 1 ;  C h a k r a v a r t y  e t  a l .  2013 ) .   BTK  i s  p r im a r i ly  
e x p r e s s e d  i n  h em a t o p o i e t i c  c e l l s ,  i n c l u d i n g  B  c e l l s ,  m o n o c y t e s ,  a n d  m a c r o p h a g e s  (B u r g e r  2 0 1 4 ) .   
I n  h um a n s ,  BTK  l o s s - o f - f u n c t i o n  m u t a t i o n s  c a u s e  n o n l e t h a l  X - l i n k e d  a g amm a g l o b u l i n em i a ,  
r e su l t i n g  i n  r e d u c e d  B - c e l l  and  immunog l obu l in  l ev e l s  (A a l ipou r  and  Adv an i  2014 ) .   
LY 3 3 3 7 6 4 1i s  c u r r e n t l y  b e i n g  d e v e l o p e d  f o r  r h e um a t o i d  a r th r i t i s  ( RA) ,  and  a  Ph a s e  2  s tudy  i n  
p a t i en t s  w i th  RA ( I8K - MC- JPDA[ JPDA ] )  i s  o n g o i n g .   P o t e n t i a l  t h e r a p e u t i c  b e n e f i t s  of  BTK  
i n h i b i t i o n  f o r  RA  i n c l u d e  r e d u c e d  p a t h o g e n i c  B - c e l l  au to an t ibody  p rodu c t i o n  a n d  m y e l oi d - c e l l  
p ro in f l amm a to ry  cy tok in e  p rodu c t i o n  a n d  i n h i b i ti o n  o f  m a s t  c e l l  a n d  b a s o p h i l  d e g r a n u l a ti o n  
(Ho rwoode t  a l .  2012 ) .   
LY 3 3 3 7 6 4 1  d em o n s t r a t e s  p o t e n t ,  i r r e v e r s i b l e  BTK  i n h i b i ti o n  i n  BTK  e n z ym e  a s s a y s ,  c e l l - b a s e d  
BTK  p h o s p h o r y l a t i o n  a s s a y s ,  a n d  BTK  o c c u p a n c y  a s s a y s.   
T h e  i n  v i v o  a c t i v i ty  o f  LY 3 3 3 7 6 4 1  w a s  i n v e s t i g a t e d  i n  m o u s e  a n d  r a t  m o d e l s  o f  c o l l a g e n -
i n d u c ed  a r th r i t i s  and  m ou s e  m od e l s  o f  sy s t em i c  lupu s  e ry th em a t o s u s .   LY 3 3 3 7 6 4 1  w a s  e f f e c t i v e  
i n  t h e  m o u s e  a r t h r i t i s  m od e l ,  wh e r e  i t  h a l t ed  p rog r e s s i on  o f  c l in i c a l  a r th r i t i s  a n d  s i g n i f i c a n t l y  
d im i n i s h e d  s t r u c t u r a l  d am a g e  i n  t h e  j oi n t s .   T h e  h i g h  l e v e l  o f  e f f i c a cy  f o r  c l in i c a l  d i s e a s e  a c t i v i t y  
w a s  r e p r o d u c e d  i n  t h e  r a t  a r t h r i ti s  m od e l .   LY3337641  w a s  a l s o  e f f e c t i v e  i n  a  s p o n t a n e o u s  m o u s e  
m od e l  o f  sy s t em i c  lupu s  e ry th em a t o s u s ,  w h e r e  i t  im p r o v e d  s k i n  l e s i o n s ,  r e d u c e d  p r o t e i n u r i a ,  a n d  
imp rov ed  r en a l  h i s top a tho logy  s c o r e s .   T a k e n  t o g e t h e r ,  t h e s e  r e s u l t s  s u g g e s t  t h a t  LY 3 3 3 7 6 4 1  
m a y  b e  u s e f u l  f o r  t r e a tm e n t  o f  a u t o imm u n e  d i s e a s e s ,  i n c l u d i n g  RA .
 
 
 
 
 
I8K - JE- JPDB(a )C l in ica l  Pha rmaco logy  P ro tocol Page  16
LY3337641 
 
 
 
 
 
 
 
 
 
 
Re su l t s  f rom  non c l in i c a l  s tud i e s  w i th  LY 3 3 3 7 6 4 1  a n d  th e  S tudy JPDDs a f e t y  p r o f i l e  s u p p o r t  th e
d e s ign  o f  th i s  s tudy .   
3 .3 .Bene f i t /R isk  Assessmen tCC I
No  c l in i c a l ly s i g n i f i c a n t  s a f e ty  c o n c e r n s  h a v e  b e e n  i d e n t i f i e d  a t  th e  do s e s  p ropo s ed  i n  th i s  s tudy  
f o r  LY 3 3 3 7 6 4 1.   Th e  do s e  l ev e l s  in c lud ed  in  th i s  s tudy a r e  w i t h i n  t h e  r a n g e  o f  d o s e s  s t u d i e d  
p r e v i o u s l y ,a n d  t h e  t o l e r a b i l i t y  h a s  b e e n  c o n f i rm e d.   
M o r e  i n f o rm a ti o n  a b o u t  t h e  k n ow n  a n d  e x p e c t e d  b e n e f i t s ,  r i s k s ,  s e r i o u s  a d v e r s e  e v e n t s  (SAE s )  
a n d  r e a s o n a b l y  a n t i c i p a t e d  a d v e r s e  e v e n t s  (AE s )  o f  LY 3 3 3 7 6 4 1a r e  t o  b e  f o u n d  i n  t h e  
I n v e s ti g a t o r ’ s  Bro chu r e .   
I8K-JE-JPDB(a) Clinical Pharmacology Protoco l Page 17
LY33376414.Objectiv esand Endpoints
Table JPDB .1shows the object ives and endpo ints of the study .
Table JPDB .1. Objectives and Endpoints
Objectives Endpoints
Primary
To explore the safety and tolerability of LY3337641 in 
healthy  Japanese and Caucasian subjects AEs and SAEs
Secondary
To estimate the PK parameters of single and multiple 
doses of LY3337641 following oraladministration in 
healthy  Japanese and Caucasian subjectsCmaxand AUC
Exploratory Objectives
1. To explore the PDfollowing single and multiple 
doses of LY3337641 in healthy  Japanese and 
Caucasian subjects  
2. To explore the safety, tolerability, PK, and PD of 
LY3337641 in Japanese subjects in relation to 
Caucasian subjects
3. To explore the effect of LY3337641 on ECG finding s
in healthy  Japanese and Caucasian subjects 1. BTK occupancy
2. AEs, SAEs, C max, AUC, and BTK occupancy
3. ECG parameters 
Abbreviations: AEs =adverse event s; AUC =area under the plasma concentration -time curve; BTK =Bruton’s 
tyrosine kinase; Cmax=maximum drug concentration; ECG =electrocardiogram; PD=pharmacodynamic s; 
PK=pharmacokinetic (s); SAE s =serious adverse event s.
I8K-JE-JPDB(a) Clinical Pharmacology Protoco l Page 18
LY33376415.Study  Design
5.1. OverallDesign
This is a single -site, subject -and invest igator -blind, randomized, placebo -controlled, SDand 
MD study  to assess the safet y, tolerabilit y, PK, and PD of LY3337641 in healt hy Japanese and 
Caucasian subjects.  Subjects will be rando mized to LY3337641 within each cohort as shown in 
Figure JPDB .1.  All cohorts will be randomize d in a 3:1 rati o of LY3337641 to pl acebo. MD 
Cohort 1 (30mg QD for 2 weeks ) and Cohort 5 (optional)will consist of 12 subjects (8 Japanese 
and 4 Caucasian). SD Cohorts2, 3
,and 4 (5, 80, and 160 mg SD) will consist of 8 subjects 
(4Japanese and 4 Caucasian).  For each MD cohort, 6 Japanese subjects and 3 Caucasian 
subjects will receive LY3337641 ,while 2 Japanese subjects and 1 Caucasian subject will 
receive placebo.  For each SD cohort , 3Japanese subjects and 3Caucasian subjects will 
receive LY3337641 , while 1 Japanese subject and 1 Caucasian subject will receive placebo.
Invest igational product (IP) will beadministered orally .  Cohorts 1, 2, and 3 may be conducted in 
parallel if the site is able to accommodate more than 1 cohort at a time ;however, priorit y will be 
given to dose Cohort 1, since the timing of thiscohort will determine the timing of the interim 
analysis .  Cohort 4 will be started based on the safety  assessment up to Day 3(48 hours 
postdose) of Cohort 2 .If the dose level/regimen for Cohort 1 i s not tolerated o
r there is a need to 
dose m ore subjects to assess safet y,a daily  dose of 30 mgor less(QD or BID) m ay be given in 
Cohort 5based on the findings fro m Cohort 1.   This will be discussed and agreed upon by the 
investigator and the Lilly clinical pharmaco logist.  Therando mizat ion rulesand procedures will 
be the same as Cohort 1 .
Figure JPDB .
1illustrates the study  design.
I8K-JE-JPDB(a) Clinical Pharmacology Protoco l Page 19
LY3337641Abbreviations: BID =twice daily; FU=follow -up; JP =Japanese; LY=LY3337641; 
Pb= placebo ; QD=once daily .
*Dose , regimen ,and subject number may change for optional cohort .
Figure JPDB .1. Illustration of study design for Protocol I8K-JE-JPDB .
5.2. Number of Participants
Up to 60subjects may be enro lled sothat approximately 36 to 48 subjects complete the study.
5.3. End of Study Definition
End of the study is the date of the last visit or last scheduled procedure shown in the Schedule o f 
Activities(Secti on 2) for the last subject.
5.4. Scientific Rationa le for Study Design
This is a single -site, subject -and invest igator -blind, randomized, placebo -controlled, SDand 
MDstudy  in healthy Japanese and Caucasian subjects. This study  is conducted to support the 
inclusio n of Japanese subjects in future studies involving LY3337641.  Healthy Caucasian 
subjects are also included in this study for assessment of both healthy Japanese and Caucasian 
subjects .  The number of subjects in this study is deem ed sufficient for the safet y, tolerabilit y, 
and PK data that will be assessed in both Japanese and Caucasian subjects .  Intensive assessment 
of electrocardi ogram s (ECG s)will be done in this study , since thorough ECG data ha venot bee n 
obtained so far.  The study  will be subject and investigator blind, with the subjects, invest igators, 
and site staff unaware of actual treatment ( LY3337641 or placebo) but aware of dose level 

I8K - JE- JPDB(a )C l in ica l  Pha rmaco logy  P ro tocol Page  20
LY3337641a s s i g n e d  t o  t h e  c o h o r t .   T h i s  d e s i g n  i s  b e i n g  u s e d  t o  m i n im i z eb i a s  i n  s a f e ty  and  to l e r a b i l i t y  
a s s e s sm e n t s .
5 .5 .Jus t i f ica t ion  fo r  Dose
CC I  
 
 
 
 
 
 
 
  
 
  
 
 
  
 
 
 
 
 
  
 
 
 
 
 
  
I8K-JE-JPDB(a) Clinical Pharmacology Protoco l Page 21
LY33376416.Study  Population
Eligibilit y of subjects for study  enrollment will be based on the results of screening medical 
history , physical  examinat ion, vital signs, clinical laboratory  tests ,and ECG .  
A chest x -ray will be com pleted at screening unless one has been obtained within the past 
12months, and the x -ray and/or report are available for review.
The nature of any condi tions present at the time of the physical examinat ion and any preexist ing 
condi tions will  be docum ented.
Screening may occur up to 28 days prior to Day 1 .  Subj ects who are not enrolled within 28 days 
of screening m ay be subjected to an addit ional medical assessment and/or clinical measurements 
to confirm their eligibilit y.
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, are not permitted.
6.1. Inclusion Criteria
Subjects are eligible for inclusio n in the study  only if they  meet all  of the f ollowing criteria at 
screening and/or enrollment:
[1] are overtly healt hy males and females , as determined by  medical  history  and 
physical exa minat ion
[1a] male subjects:
agree to use an effect ive method of contraception (barrier contraceptives, 
such as latex condo ms, or complete abst inence from sexual intercourse 
withwomen ) for the durati on of  the study  and 3 months following the l ast 
dose of IP
[1b] female subjects:
wom en of childbearing potential may  parti cipate and include those who test 
negat ive for pregnancy  prior to ini tiation of treatment (as indicated by  a 
negat ive serum pregnancy test at the screening visit fo llowed by  anegat ive 
urine pregnancy test within 24 hours prior to exposure )and agree to remain 
abstinent or use either 1highly  effect ive method of contraception (such as 
combinat ion oral  contraceptive ,implanted contraceptive
,or intrauterine 
device) or a com binat ion of 2effect ive methods of contraception (such as 
male or female condom wit h spermicide, diaphragm wit h spermicide ,
orcervical sponge) during the study  and for 4 weeks following the last 
dose ofthe IP
wom en not of child bearing potential may participate and include those 
who are:
I8K-JE-JPDB(a) Clinical Pharmacology Protoco l Page 22
LY3337641A. infertile due to surgical sterilizat ion(hysterectomy, bilateral oophorectomy, or 
tubal  ligation)performed at l east 6 m onths pri or to dosing or congenital ano maly 
such as müllerian agenesis or
B. postmenopausal, defined as eit her
i. A woman aged 50 years or older who has an intact uterus, is not on hormone 
therapy , and hashad either
a) cessat ion of menses for at least 1 y ear or
b) 6 to 12 m onths of spontaneous amenorrhea with a fo llicle -stimulating 
horm one>40 m IU/mL or
ii. A wo man aged 55 years or older who is not on horm one therapy  and has had at 
least 6 months of spontaneous amenorrhea or
iii. A woman aged 55 years or olderwith a diagnosis of menopause prior to 
starting hormone replacement therapy
[2] are aged 20to 64years, inclusive ,at screening
[3] have a body  mass index of 18. 0to 32.0 kg/m 2, inclusive, at screening
[4] have clinical laboratory  test resul ts wi thin norm al reference range for the 
popul ation or invest igative site or results with acceptable deviat ions that a re 
judged to be not clinically significant by  the investigator
[5] have venous access sufficient to allow for blood sampling as per the protocol
[6] are reliable and willing to make themselves available for the duration of the 
study  and are willing to foll ow study  procedures
[7] are able and willing to give signed informed consent
[37] are 1stgenerati onJapanese or Caucasian.
To qualify  as a subject of 1stgenerat ion Japanese ori gin, the subject, the 
subject’s bio logical parents, and all o f the subject’s bio
logical  grandparents 
must be of exclusive Japanese descent and born in Japan.
6.2. Exclusion Criteria
Subjects will be excluded fro m study  enro llment if they meet any o f the following cri teria at 
screening and/or enrollment:
[8] are invest igative site personnel direct ly affiliated with this study  and thei r 
immediate families.  Immediate family is defined as a spouse, biological or 
legal guardian, child, or sibling
[9] are Lilly  or Covance empl oyees
I8K-JE-JPDB(a) Clinical Pharmacology Protoco l Page 23
LY3337641[10] are currently enrolled in a clinical  trial involving an IPor off -label use of a 
drug or device or are concurrent ly enro lled in any other type of medical 
research judged not to be scient ifically or medically co mpat ible with 
thisstudy
[11] have participated, within the last 30 days, in a clinical trial in volving an IP.  
Ifthe previous IPhas a long half -life, 3 months or 5 half -lives (whichever is 
longer, if known) should have passed
[
12]have previously completed or withdrawn fro m this study  or any  other study  
investigat ing LY3337641 and have previously received the IP
[13] have known allergies to LY3337641, related compounds or any  com ponents 
of the form ulation, or hi story  of significant atopy
[14]have an abnormalit y in the 12 -lead ECG that, in the opinion o f the 
investigator, increases the risks associated with participat ing in the study or
affects or confounds the QTc analysis (the ECG waveform morphology  or
rhythm are incom patible wi threliable measurement of ECG intervals) or have 
Fridericia-corrected QT i nterval ( QTcF ) >450 m sec for males and >470 msec 
for females
[15]have an abnormal blood pressure or pulse rate (supine) as determined by 
theinvest igator
[16]have a significant hist ory of or current cardi ovascular, respi ratory , hepatic, 
renal, gastrointestinal (chol ecystectomy  not acceptable), endocrine, 
hematol ogic, derm atologic, or neurol ogic disorders capable of significant ly 
altering the absorpti on, m etabo lism, or eliminat ion of drugs; of const ituting a 
risk when taking the IP; or of interfering wit h the interpretation of data
[17]have known or ongoing psychiatric disorders
[18]regul arly use known drugs of abuse and/or show posit ive findings on urinary 
drug screening
[19] show e vidence of human immunodeficiency  virus (HIV) infecti on and/or 
positive human HIV ant ibodies
[20]show evidence of hepatit is C and/or positive hepat itis C ant ibody
[21]show evidence of hepatit is B and/or positive hepat itis B surface 
antigen (HBsAg)
[22]are posi tive for hepatit is B core antibody (HBcAb+)
[23]are wom en who are lactating
[24]have used or intend to use over -the -counter or prescript ion medication, 
including herbal medicat ions, within 14 days pri or to dosing
[25]have donated blood of more t han 500 mL within the month prior to screening
I8K-JE-JPDB(a) Clinical Pharmacology Protoco l Page 24
LY3337641[26]have an average weekly  alcohol  intake that exceeds 21 units per week and are 
unwilling to follow instructi ons in Sect ion 6.3.2 (1unit= 12 ounces or 
360mLof beer,
5ounces or 150 mL o f wine ,and 1.5ounces or 45 mLof 
distilled spirits)
[27]are subjects whose tobacco consumpt ion is more than 10 ci garettes per day  or 
the equivalent or subjects who are not willing to refrain fro m smoking for 
48hours prior to clinical research unit ( CRU )admissio n and during CRU stay
[28]have a history  of, in the opinio n of the invest igator, excessive methylxanthine 
use wi thin the previous 3 months or are unwilling to abide by restrictions as 
specified in Section 6.3.2 . Excessive intake is defined as more than 6 units 
ofcaffeine per day; 1caffeine unit is contained in the fo llowing i tems :  
1(177 mL) cup of coffee, 1 (355 mL) cup of tea, 2 (355 mL) cans of co la, 
or3ounces (85g
) of chocolate
[29] have had symptomat ic herpes zoster wi thin 3 m onths of screening, as 
determined by clinical history
[30] have act ive or latent tuberculosis (TB) based on a posit ive medical history , 
examinat ion, and/or TB test results.  QuantiFERON ®-TB Gold Plus test 
(QFT -Plus or equivalent) will be u
sed for TB testi ng, and subjects mu st test 
negat ive to participate
[31] have a screening chest x -ray with evidence of medically significant disease, 
such as malignancy, infect ion, pulmo nary disease, or cardi ac failure
[32] have received live vaccine(s) wit hin 1 mo nth of screening or intend to during 
the study
[33] are immunocompro mised
[34]in the opinio n of the invest igator or sponsor, are unsuitable for inclusio n in 
thestudy
[35] have had exposure to significant diagnost ic, therapeutic, or 
employment -related radi ation within 12 m onths prior to dosing (eg, serial 
x-ray or com puted tom ography  scans, barium meal, current emplo yment in a 
job requiring radiat ion exposure monitoring)
[
36]have a history  of consti pation or have had acute const ipation within 3 we eks 
prior to admissio n
6.3. Lifestyle and/or Dietary Requirements
Throughout the study , subjects m ay undergo medical assessments and review of compliance with 
requi rements before continuing in the study .  
6.3.1. Meals and Dietary Restrictions
Before each morning dose in the SD and the MD cohorts , subjects will be fasted overnight for at 
least 10 hours fo llowing a light supper on the evening before .  Following dosing, subjects will 
I8K-JE-JPDB(a) Clinical Pharmacology Protoco l Page 25
LY3337641fast for a period of 4 hours until lunch (for the MD cohorts ,fasting after dosing will occur on 
Days 1 and 15 only; on all  other dosing days in the MD cohorts , subjects should consume a 
non-standardized breakfast approximately 1 hour after dosing). For BID dosing , if studied, 
subjects will be fasted 1 hour before a nd after the evening dos e.  During fast ing, no fluids are 
allowed except for water; however, water is not allowed from 2 hours predose until 1 hour 
postdose (apart from the water taken with the dose) .  
6.3.2. Caffeine, Alcohol, and Tobacco
Caffeine —Subjects shoul d not be allowed caffeine consumpt ion for 48 hours prior to all study 
visits and during CRU stay s.  
At other times during the outpatient period, subjects will be
allowed to maintain their regular caffeine consumption.
Alcohol —Alcoho l consumpt ion is not allowed from 48hours prior to all study  visits and during
CRU stay s.  At all other times, alcohol consumpt ion shoul d be limi ted to no m ore than 2 units 
per day (1 uni t = 12 ounces or 360 mL of beer, 5 ounces or 150 mL o fwine, and 1.5 ounces or
45mL of dist illed spirits).
Tobacco —Subjects will be asked to refrain fro m smoking f or approximately  48hours prior to 
CRU admissio n and during CRU stays .  
During the fo llow-up peri od, subjects will be asked to 
refrain fro m smoking f or 2 hours pri or to study visits.
6.3.3. Activity
No strenuous exercise will be allowed for 48 hours prior to admissio n and during the study .
6.4. Screen Failures
Individuals who do not meet the criteria for participation in this study  (screen failure) m aybe 
re-screened.  Individuals ma y be re -screened once wi th Lilly  clinical pharmacol ogist’s approval .  
The interval between re -screenings should be at least 2 weeks.  Each time re -screening is 
perform ed, the individual must sign a new informed consent form (ICF) and will be assigned a 
new ident ification number .
I8K-JE-JPDB(a) Clinical Pharmacology Protoco l Page 26
LY33376417.Treatment
7.1. Treatment Administ ered
This study  involves a numerical compar ison o f LY3337641 (30mg QDin MD cohorts and 5, 80,
and 160 mg in SD cohorts) withplacebo , when administered orally .  
The study  drug i s supplied
as tabl ets containing 5 or20mg of LY3337641 with matching placebo tablets (Table JPDB .2).  
LY3337641 and placebo will be administered orally with ap proximately  200 mL of room 
temperature water in the morning of each dosing day  with the subject in a sitting position.  
Subjects will not be allowed to lie supine for 2 hours after dosing, unless clinically indicated 
oras needed for study  procedures.
Table JPDB .
2. Treatment Administered
Cohort Dose Number of Tablets
Cohort 1LY 30 mg QD1x 20-mg LY tablet
2 x 5-mg LY tablets
Placebo 30 mg QD1 x 20- mg placebo tablet
2 x 5-mg placebo tablets
Cohort 2LY 80 mg 4x 20-mg LY tablets
Placebo 80 mg 4 x 20- mg placebo tablets
Cohort 3LY 5 mg 1 x 5-mg LY tablet
Placebo 5 mg 1 x 5-mg placebo tablet
Cohort 4LY 160mg 8x 20-mg LY tablet s
Placebo 160mg 8x 20-mg placebo tablet s
Abbreviations:  LY =LY3337641 ; QD =once daily .
The invest igator or designee is responsible for:
explaining the correct use of the IPto the subject, 
verifying that instructions are fo llowed properly,
maintaining accurate records of IPdispensing and collect ion,
and returning all unused medicat ion to Lilly or its designee at the end of the study .
Note : In some cases, sites may destroy  the m aterial  if, during the invest igativesite select ion, the 
evaluator has verified and documented that the site has appropriate facilit ies and wri tten 
procedure s to dispose of clinical trial materials .  
I8K-JE-JPDB(a) Clinical Pharmacology Protoco l Page 27
LY33376417.1.1. Packaging and Labeling
IP will be supplied by  the sponsor in accordance wit h current good manufacturing pract ices.  The 
materi al will be l abeled wi th a unique ident ifier for drug accountabilit y. Clinical trial materi als 
will be labeled according to the coun try’sregulatory  requirements and will be labeled with the 
ident ity of the m aterial contained in the package .  
The study  drug will be supplied as tablets containing 5 or20mg of LY3337641 with matching
placebo tabl ets. The LY3337641 5 -mg tablets and corresponding 5 -mg m atched placebo are
ident ical in appearance, and the LY3337641 20 -mg tablets and corresponding 20- mg matched
placebo are i dentical  in appearance. However, the 5 -and 20 -mg tablets are no t identical 
inappearance.
Packaging will be as fo llows:
5mg LY3337641 blister card —9 tablets
Placebo to match 5 mg LY3337641 blister card —9 tablets
20mg LY3337641 blister card —9 tablets
Placebo to match 20 mg LY3337641 blister card —9 tablets
7.2. Method of Treatment Assignment
Randomization tables for allocat ion of LY3 337641 or placebo will be prepared by  the statistician 
for the study  and provi ded to the si te pharmacists involved in dose preparation.  The allo cation 
and dispensing of the IP will be fully documented and verified by a second person.  Detailed 
records of the amounts of the IP received, dispensed, and remaining at the end of the study  will 
be maintained by the site pharmacist.
7.2.1. Selection and Timing of Doses
SDs will be administered in the morning.  For the QDcohort(s), doses will be administered at 
approximately  the same t imein the morning on each day for each subject
.  Ifthe BID regimen is 
tested in Cohort 5, the dose will be administered in the morning and the evening.  The evening 
dose should be taken 12 hours apart from the morning dose.  On Day  15, only the morning dose 
will be administered.
Meal condit ions are discussed in Sect ion 6.3.1 .  The actual time o f all dose administrations will 
be recorded in the subject’s electroni c case report form  (eCRF).
7.3. Blinding
Blinding will be maintained throughout the c onduct of the trial unt il all data are cleaned to an 
acceptable level o f qualit y and l ocked .  The details are included in the Blinding/ Unblinding 
Plan(Appendix 6 ).
The site pharmacist will be responsible for dispensing the IP to the subjects in a blinded manner.  
The invest igator and subjects shoul d remain blinded to study treatm entwithin each cohort
throughout the conduct of the study .
I8K-JE-JPDB(a) Clinical Pharmacology Protoco l Page 28
LY3337641If a subject’s study  treatm ent assignment is unblinded, the subject must be discont inued from the 
study , unless the invest igator obtains specific approval fro m a Lilly clinical pharmaco logist or 
clinical research physician or for the study  parti cipant to continue in the study .  
In case of an emergency , the invest igator has the sole responsibilit y for determining if unblinding 
of asubject’s treatm ent assi gnment i s warranted for m edical management of the event.  S ubject’s
safet y must al ways be the first considerat ion in making such a determinat ion.  If the invest igator 
decides that unblinding is warranted, the invest igator should make every effort to contact the 
Lilly clinical pharmaco logist or clinical research physician prior to unblinding a study  subject’s 
treatm ent assi gnment ,unless this could delay emergency treatment of the subject .  If a study  
subject’s treatment assignment is unblinded, Lilly must be notified immediately.
7.4. Dose Modification
7.4.1. Dose Escalation
All doses in this study  have been previously tested and shown to be well tolerated in Study  JPDD.  
However, Japanese subjects have not received LY3337641 previously . The dose escalat ion 
decisio n will be made based on the safet y data from both Japanese and Caucasian subjects up
toDay 3 (48 hours postdose) of 80- mg SD administrati on (Cohort 2) to proceed to the 160 mg 
SDcohort (Cohort 4).  
Safety data forthe 80-mg SDwill be the primary  criteria for dose escalat ionto the 160-mg SD.  
In addit ion, if available at the time of dose escalat ion decisio n, PK (Cmax, AUC, and clearance ) 
resul ts maybe used as supporting data for dose escalat ion, but such data are not required.  No 
dose escalat ion can occur without prior discussio n and agreement between the invest igator and 
theLilly clinical pharmaco logistor clinical research physician .  
Safety data, in particular AEs, SAEs ,and adverse laboratory  abnorm alities, will be 
independent ly assessed by the invest igator and will be considered related to the IP,unless 
thereis clear evidence that the event is not related.  
After review of these data, an agreement on the appropriate dose escalat ion will be made by the 
investigator and sponsor for the 160-mg SDcohort.  The m agnitude of  the dose escal ation may 
be reduced fo llowing data revi ew,butthe highest SDwill not exceed 160 mg.
If any o f the following scenarios occur, dosing at the current level and further dose escalat ion 
will be stopped until the safet y data can be reviewed :
1) 1 or more subjects experience a
nSAE
2) 2 or more subjects experience a clinically significant event that is related to 
LY3337641 administration
3) greater than 3subjects at 1 dose level experience moderate treatment -related AEs
that impair normal act ivities
After the safet y review is co mpleted, 
if Cohort 2 dosing ha snot been completed, dosing may 
resum e if agreed upon by the investigator and sponsor.  Once all data fro m Cohort 2 has been 
I8K-JE-JPDB(a) Clinical Pharmacology Protoco l Page 29
LY3337641obtained, an agreement on the appropriat e dose escalat ion will be made by the invest igator and 
sponsor for the 160- mg SDcohort or a l ower dose .
7.5. Preparation/Handling/Storage/Accountability
Only participants enro lled in the study  may receive IPand only authorized site staff may supply 
or adminis ter study  treatm ent. All study  treatm ents shoul d be stored in a nenvironmentally  
controlled and mo nitored (manual or automated) area in accordance with the labeled storage 
condi tions wi th access limited to the invest igator and authorized site staff .
The invest igator, institution, or the head of the medical inst itution (where applicable) is 
responsible for study  treatm ent accountabilit y, reconciliat ion, and record maintenance ( such as
recei pt, reconciliat ion,and final disposit ion records) .
7.6. Treatment Compl iance
The IPwill be administered at the CRU , and documentati on of  treatm ent administrati on will 
occur at the CRU .
7.7. Concomitant Therapy
If the need for concomitant medicat ion arises, inclusi on or continuat ion of the subject may be at 
the discret ion of the i nvest igator after consultation with a Lilly clin ical pharmaco logist or 
clinical research physician.  Any  addi tional medicati on used duri ng the course of the study  
must be documented.
7.8. Treatment after the End of the Study
This sect ion is not applicable for t his study.
I8K-JE-JPDB(a) Clinical Pharmacology Protoco l Page 30
LY33376418.Discontinuation Criteria
8.1. Discontinuation from Study Treatment
Discontinuati on of  the IPfor abnormal liver tests should be considered by the invest igator when 
a subject m eets one of the fo llowing condi tions aft er consul tation wi th the Lilly -designated 
medical mo nitor:
Alanine aminotransferase (ALT) or aspartate aminotransferase ( AST) >5X upper limit 
ofnorm al (ULN)
ALT or AST > 3X ULN along with one of the fo llowing criteria
osustained for more than 2 weeks or
ototal bilirubin level (TBL) >2X ULN or
oprothrombin t ime >1.5X ULN or
othe appearance of fat igue, nausea, vo miting, right upper -quadrant pain or 
tenderness, fever, rash, and/or eosinophilia (>5%)
Alkaline phosphatase (ALP ) >3X ULN
ALP>2.5X ULN and TBL >2X ULN
ALP>2.5 ULN with the appear ance of fat igue, nausea, vo miting, right quadrant pain or 
tenderness, fever, rash, and/or eosinophilia (>5%)
In addit ion, subjects will be discont inued fro m the IP in the following circumstances:
The invest igator decides that the subject should be disconti nued fro m the IP  
The subject requests tobe discont inued fro m the IP
Subject experience s a
nSAE or clinically significant event that is related to 
LY3337641 administration, or
Subject experiences moderate treatment -related AEs that impair normal activities
When this situat ion arises, the invest igator shoul dinform a Lilly  clinical pharmacol ogistor 
clinical research physician .
When s ubjects discont inue the IPearly ,procedures to be perform ed will be discussed between 
the invest igator and the Lilly clinical pharmaco logist or clinical research physician.
8.1.1. Discontinuation of Inadvertently Enrolled Subjects
If the Sponsor or invest igator ident ifies a subject who did not meet enrollment criteria and was 
inadvertent ly enro lled, a discussio n must occu r between the Lilly  clinical pharmacol ogistor 
clinical research physician and the invest igator to determine if the subject may cont inue in the 
study .  If both agree it is medically appropriate to continue, the invest igator must obtain 
docum ented approval  from the Lilly  clinical pharmacol ogistor clinical research physician to 
allow the inadvertent ly enrolled subject to continue in the study  with or wi thout continued 
treatm ent wi th IP.
I8K-JE-JPDB(a) Clinical Pharmacology Protoco l Page 31
LY33376418.2. Discontinuation from the Study
Subjects will be discont inued in the following ci rcum stances:
Enrollment in any other clinical trial invo lving an IPor enrollment in any other ty pe of 
medical research judged not to be scient ifically or medically co mpat ible with this study
Parti cipation in the study  needs to be stopped for medical, safet y, regul atory , or other 
reasons consistent with applicable laws, regulations, and good clinical pract ice
Invest igator Decisio n
othe invest igator decides that the subject should be discontinued from the study
oif the subject, for any  reason, req uires treatment with another therapeutic agent 
that has been demo nstrated to be effect ive for treatment of the study  indicat ion, 
discontinuat ion from the study  occurs pri or to introducti on of  the new agent
Subject Decisio n
othe subject or designee (for exam ple, parents or l egal guardi an)requests to be 
withdrawn from  the study
Subjects who discont inue the study  early  will have end -of-study  procedures performed as shown 
in the Schedule of Act ivities(Secti on 2).
8.3. Subjects Lost to Follow -up
A subject will be considered lost to follow -up if he or she repeatedly  fails to return for scheduled 
visits and is unable to be con tacted by  the study  site.  Site perso nnel are expected to make 
diligent attempts to contact subjects who fail to return for a scheduled visit or were otherwise 
unable to be fo llowed up by  the si te.
I8K-JE-JPDB(a) Clinical Pharmacology Protoco l Page 32
LY33376419.Study Assessments and Procedures
Secti on 2lists the Schedule of Act ivities, detailing the study  procedures and their timing 
(including tolerance limit s for timing).
Appendix 2 lists the laboratory tests that will be performed for this study.
Appendix 5 provi des a summary  of the m aximum  number and vol ume of invasive samples, for 
all sampling, during the study .
Unless otherwise stated in subsect ions below, all s amples collected for specified laboratory  tests 
will be destroy ed wi thin 60 days of receipt of confirmed test resul ts.  Certain samples may be 
retained for a longer period, if necessary , to com ply with applicable laws, regulat ions, or 
laboratory  certificati on standards.
Invest igators must document their review of each laboratory  safety  report.
9.1. Efficacy Assessments
This section is not applicable for this study.
9.2. Adverse Events
Invest igators are responsible for monitoring the safety of subjects who have entered this study  
and for al erting Lilly  or its designee to any  event that seems unusual, even if this event may be 
considered an unant icipated benefit to the subject.
The invest igator is responsible for the appropriate medical care of subjects during the study.
The invest igator remains responsible for fo llowing, through an appropriate health care option, 
AEs that are s erious or otherwise medically important, considered related to the IP or the study , 
or that caused the subject to discontinue the IPbefore complet ing the study .  The subject should 
be followed unt il the event resolves, stabilizes with appropri ate di agnost ic evaluat ion, or i s 
reasonably  explained.  The frequency  of follow-up evaluat ions of the AE is left to the discret ion 
of the invest igator.
After the ICF is signed, s tudy site personnel will record ,viaeCRF ,the occurrence and nature of 
each subject’s pre exist ing condit ions, including clinically significant signs and symptoms of the 
disease under treatment in the study .  Addit ionally , site personnel will record any  change in the 
condi tion(s) and the occurrence and nature of any AEs.  
The invest igator will interpret and docum ent whether or not anAE has a reasonab lepossib ility 
of being related to study treatment , or a study procedure, taking into account the disease, 
concomitant treatment ,or pathol ogies.  
A “reasonable possibilit y”means that there is a cause -and-effect rel ationship between the IP, 
study  device ,and/or study  procedure and the AE.
Planned surgeries should not be reported as AEs ,unless the underlying medical condit ion has 
worsened during the course of the study .
I8K-JE-JPDB(a) Clinical Pharmacology Protoco l Page 33
LY3337641If a subject’s IP is discont inued as a result of an AE, study  site personnel  must report thi s to Lilly 
or its desi gnee via eCRF.
9.2.1. Serious Adverse Events
An SAE is any  AE from this study  that resul ts in one of the fo llowing:
death
initial or prolonged inpati ent hospi talizat ion
a life- threatening experience (that is, immediate risk of dying)
persistent or significant disabilit y/incapacit y
congenital ano maly/birth defect
event s considered significant by  the invest igator based upon appropriate 
medical judgment
Study site personnel  must al ert Lilly ,or its designee ,of any SAE wi thin 24 hours of invest igator 
awareness o f the event via a sponsor -approved method.  If alerts are issued via telephone, they 
are to be immediately fo llowed wi th official  notificati on on study-specific SAE forms.  
This 24-hour notificat ion requirement refers to the init ial SAE info rmation and all fo llow -up 
SAE informat ion.
Pregnancy (maternal or paternal exposure to IP) does not meet the definit ion of an AE.  
However, to fulfill regulator y requi rements any  pregnancy  should be reported following the 
SAE process to collect data on the outcome for both mother and fetus.
9.2.1.1. Suspected Unexpected Serious Adverse Reactions 
Suspected unexpected serious adverse react ions (SUSARs) are serious events t hat are not listed 
in the Invest igator’s Brochure and that the invest igator i dentifies as related to the IPor 
procedure.  United States 21 CFR 312.32 and European Unio n Clinical Trial Directive 
2001/20/EC and the associated detailed guidances or nati onal regulatory  requi rements in 
participat ing countries require the reporting of SUSARs .  Lilly has procedures that will be 
followed for the recording and expedited reporti ng of SUSARs that are consistent with global 
regul ations and the associated detailed guidances.
9.2.2. Complaint Handling
Lilly co llects product complaints on IPs and drug delivery  systems used in clinical trials in order 
to ensure the safet y of study  partici pants, m onitor quali ty, and to facilitate process and product 
improvements.
Subjects should be instructed to contact the invest igator as soon as possible if he or she has a 
complaint or probl em wi th the IPor drug delivery system so that the situation can be assessed.
I8K-JE-JPDB(a) Clinical Pharmacology Protoco l Page 34
LY33376419.3. Treatment of Overdose
For the purposes of this study , an overdo se of LY3337641 is considered any dose higher than the 
dose assigned through rando mizat ion.
Refer to the Invest igator ’s Brochure.
9.4. Safety
9.4.1. Laboratory Tests
For each subject, laboratory  tests detailed in Appendix 2 shoul d be conducted accordi ng to the 
Schedule of Act ivities (Secti on2)and as clinically indicated .  
9.4.2. Vital Signs
For each subject ,vital sign measurem ents including body (oral) temperature, supine and standing 
blood pressure ,and pulse rate should be conducted according to the Schedule of Act ivities 
(Secti on 2)and as clinically indicated .  
Subjects will rest in the supine posit ion for at least 5 minutes and have supine blood pressure and 
pulse rate measured.  Subjects will then stand for 3 minute s and have standing blood pressure 
and pulse rate measured.
If the subject feels unable to stand, only supine vit al signs will  be recorded .  
Unscheduled orthostatic vital signs should be assessed, if possible, during any AE of dizziness or 
posture -induced symptom s.  Addi tional vital signs may be m easured during each study  period if 
warranted and agreed upon between the sponsor and invest igator.
9.4.3. Electrocardiograms
For each subject, ECGs should be collected according to the Schedule of Activit ies (Secti on 2)as 
clinically indicated andthe study -specific recommendat ions included in the Manual o f 
Operati ons for the study .  
Any clinically  significant findings from ECGs that result in a diagnosis and that occur after the 
subject receives the first dose of the IPshould be reported to Lilly ,or its desi gnee ,as an AE 
viaeCRF .  
For each subject, a 12 -lead digital ECG will be c ollected intriplicate accordi ng to the Schedule 
of Activities(Secti on 2).  ECGs must be recorded before collecting any blood for safet y or PK 
tests.   Subjects must be supine for approximately 5 to 10 minutes before ECG collect ion and 
remain supine but awake during ECG collection.  Consecut ive triplicate ECGs will be obtained 
at approximately 1-minute intervals.  ECGs may be administered at addit ional times, when
deem ed clinically  necessary .  
ECGs will be interpreted by  a qualified physician ( the invest igator or qualified designee) at the 
site 
as soon after the time o f ECG collect ion as possible, and ideally while the subject is st ill 
I8K-JE-JPDB(a) Clinical Pharmacology Protoco l Page 35
LY3337641present, to determine whethe r the subject meets entry  criteria at the relevant visit(s) and for 
immediate s ubject management, should any clinically relevant findings be ident ified.  
If a clinically significant quantitative or qualitat ive change fro m baseline is ident ified after 
enrollment, the investigator will assess the subject for symptoms (for example, palpitations, near 
syncope, syncope) to determine whether the subject can continue in the study.  The invest igator 
or qualified designee is responsible for determining if any change in subject m anagement i s 
needed and must document his or her review o f the ECG printed at the time of evaluat ion from at 
least 1 of the triplicate ECGs fro m each time point.
Digital ECGs will be electroni cally transmitted to a central ECG laboratory designated by  Lilly .  
The central ECG laboratory  will perf orm a basic quali ty control  check (for example, 
demographics and study  details) then store the ECGs in a database.  At a future time, the stored 
ECG data may be overread at the central ECG laborato ry for further eval uation of  machine -read 
measurements or to meet regulatory  requi rements.
The m achine -read ECG intervals and heart rate may  be used for data analysis and report writing 
purposes unless a cardio logist overread of the ECGs is conducted prior to com pletion of the final 
study  report (in which case the overread data would be used).
9.4.4. Other Tests 
9.4.4.1. Assessment and Management of Subjects Developing a Rash
Subjects who develop a rash should be evaluated as soon as possible.  Investigators will be 
prom pted to categori ze and di agnose the rash (per clinical judgment), assess relatedness to IP, 
and grade its severit y.  This informat ion will be recorded on the so urce document and entered 
into the eCRF.  Addit ional information related to the rash evaluat ion will also be recorded on the 
source document and will include a history  of infecti ons and allergies and recent exposure to 
prescri ption or over -the-counter medi cations, skin products, detergents, or other potential skin 
irritants.  A revi ew of  systems will be completed to assess for systemic symptoms and concurrent 
illnesses. A symptom -directed physical examinat ion should be performed, including an 
evaluat ion ofthe rash distribut ion and t ype, vital signs and temperature, and other organ systems, 
as clinically indicated. In addition, photographs and laboratory measurements should be 
obtained as clinically  indicated, according to investigator judgment. The subje ct shoul d be 
evaluated to determine whether there are any  signs or symptom s suggest ing a severe, potentially 
life-threatening condit ion.
If a subject develops a rash that is assessed as not related to IP, is transient, or is not clinically 
significant in t he opinio n of the invest igator, the IPmay be cont inued without interruption. In 
some cases, the investigator may  instead choose to interrupt the IPand restart it at a later date.  
The dates for stopping and restarting the IP shoul d be captured .  Immediate and permanent 
discontinuat ion of IPshoul d be considered for all subjects with clinically significant rash. For 
rashes deemed clinically significant, punch biopsy of the rash may also be perform ed.  In 
addition, a venous blood sample may be coll ected for PK analysis at the time of evaluat ion with 
docum entati on of  the date and time of administration of the most recent dose of IP.
I8K-JE-JPDB(a) Clinical Pharmacology Protoco l Page 36
LY3337641Subjects should be fo llowed up unt il resolut ion of the rash, to the extent possible .  The site 
shoul d manage any  rash t hat occurs during the study  according to the judgment of the 
investigator .  Interventions may include supporti ve care, pharm acotherapy , laboratory  evaluati on, 
additional skin bi opsies, and consultat ion with a derm atologist, as clinically  indicated. Data 
from these addit ional intervent ions should be provided to the sponsor as part of the AE reporting 
after being deident ified and summarized by the investigative site.
9.4.5. Safety Monitoring
The Lilly clinical pharmaco logist will monitor safety data throughout the course of the study .
Lilly will review SAEs wit hin time frames mandated by co mpany procedures.  The Lilly clinical 
pharmaco logist will consult with the functionally independent Global Pat ient Safet y therapeuti c 
area physician or clinical research scient istwhen appropriate and periodically review:
trends in safety  data
laboratory  analy tes
AEs,including monitoring of rash
If a study  subject experiences elevated ALT ≥3X ULN, ALP ≥2X ULN, or el evated total  
bilirubin ≥2X ULN, clinical and laboratory  monitorin g shoul d be ini tiated by  the invest igator.  
Details for hepat ic monitoring depend upon the severit y and per sistence of observed 
laboratory test abnorm alities.  To ensure subject safet y and co mpliance with regul atory  
guidance, the investigator i s to consult with the Lilly -designated clinical research physician
regarding collect ion of specific reco mmended clinical informat ionand fo llow-up laboratory  
tests (Appendix 4 ).
9.5. Pharmacokinetic s
At the visit s and t imes specified in the Schedule of Act ivities(Secti on 2), venous blood samples 
of approximately  
2mL each will be co llected to determine the plasma concentrations o f 
LY3337641 .  A maximum o f 3samples m ay be collected at addit ional time points during the 
study  if warranted and agreed upon between both the invest igator and sponsor.  Instructions for 
the collect ion and handling of blood samples will be provided by the sponsor.  The actual date 
and time (24- hour cl ock time) of each sampling will be recorded.
Drug concentration informat ion that m ayunblind the study  will not be reported to invest igative 
sites or blinded personnel unt il the study has been unblinded.
9.5.1. Bioanalysis
Samples will  be analyzed at a l aboratory  approved by  the sponsor and stored at a facilit y 
designated by  the sponsor .
Concentrations of LY3337641 will be assayed using a validated liquid chro matography -tandem  
mass spectrometry  method.  Analyses of samples collected fro m placebo -treated subjects are 
notplanned.
I8K-JE-JPDB(a) Clinical Pharmacology Protoco l Page 37
LY3337641Bioanaly tical samples collected to m easure IPconcentrations will be retained for a maximum o f 
1 year fo llowing last subject visit for the study .  During thi s time, sample sremaining after the 
bioanalyses may  be used for expl oratory  analyses such as addit ional metabo lism and/or protein 
binding work.
9.6. Pharmacodynamic s
At the visit s and t imes specified in the Schedule of Act ivities (Secti on2),venous blood of 
approximately  16mL at each time point will be collected to determine free BTK and total BTK 
amount. Peripheral  blood nuclear cells will be isolated. Lysates of the periph eral blood nucl ear 
cells will be used to determine the concentrations of com pound free BTK and total BTK using an 
enzyme
-linked immunosorbent assay –based methodology . 
The sample(s) will be stored for up to a maximum  of 1year after the l astsubject visit for the 
study  at a f acility selected by  the sponsor.   
9.7. Genetics
A blood sam ple will be collected for pharmacogenetic analysis as specified in the Schedule of 
Activities(Secti on 2), where local regulat ions allo w.  
Samples willnotbeused to conduct unspecified disease or populat ion genet ic research either 
now or in the future.  Samples will be used to investigate var iable exposure and response to 
LY3337641 and to investigate genetic variants thought to play  a rol e in the perceived mechanism 
of action of  LY3337641 .  Assessment of variable response may  include evaluat ion of AEs or 
differences in efficacy.  
All samples will be coded wi th the subject number.  These samples and any
 data generated can 
be linked back to the subject only by the invest igativesite personnel .  
Samples will  be retained for a m aximum  of 15 y ears after the last subject visit, or for a shorter 
period iflocal regulat ionsand/or ERBs (ethical review boards )impose shorter time limit s, for 
the study  at a f acilit y selected by Lilly  or its designee .  This retention period enables use of new 
techno logies, response to regulatory  quest ions, and invest igation of variable response that may 
not be observed unt il later in the devel opment of LY3337641 or after LY3337641 is 
commercially  available.  
Molecula r techno logies are expected to improve during the 15 -year storage period and therefore 
cannot be specifically  named.  However, e xisting approaches include who le geno me or exome 
sequencing, geno me wide association studies, multiplex assays, and candidate ge ne studi es.  
Regardless of thetechno logy utilized, data generated will be used only  for the specific research 
scope described in this sect ion.  
9.8. Biomarker s
Biomarker research is performed to address questions of relevance to drug di sposi tion, target 
engag ement, PD, mechanism of act ion, variabilit y of patient response (including safety ), and 
clinical outcome.  Sample co llection is incorporated into clinical studies to enable examinat ion of 
I8K-JE-JPDB(a) Clinical Pharmacology Protoco l Page 38
LY3337641these quest ions through measurement of bio molecul es including DNA, R NA, proteins, lipids, 
and other cellular elements .  
Serum , plasma, and/or whole blood RNA samples for nonpharmacogenet ic biomarker research 
may be collected at the times specified in the Schedule of Act ivities (Secti on 2) where l ocal 
regul ations allow.
Samples will  be used for research on the drug target, disease process, variable response to 
LY3337641 , pathway s associ ated wi th disease s related to the immune system , mechanism  of 
action of  LY3337641 , and/or research method, or for validat ing diagnostic tools or assay(s) 
related to di sease s related to the immune system .
All samples will be coded with the subject numb er.  These samples and any  data generated can 
be linked back to the subject only by the invest igative site personnel.  
Samples will  be retained for a m aximum  of 15 y ears after the last subject visit, or for a shorter 
period if local  regulat ions and/or ERB s impose shorter time limits, at a facilit y selected by  Lilly .  
This retention period enables use of new techno logies, response to regulatory  quest ions, and 
investigat ion of variable response that may not be observed unt il later in the development of 
LY333 7641 or after LY3337641 is commercially available.  
9.9. Health Economics
Thissection is not applicable for this study.
I8K-JE-JPDB(a) Clinical Pharmacology Protoco l Page 39
LY333764110. Statistical Considerations and Data Analysis
10.1. Sample Size Determination
Up to 60subjects may be enro lled so that approximately 36 to 48 subjects complete the study.
The sample size is customary  for Phase 1 studi es evaluat ing safet y, PK, and/or PD parameters 
and is not based on the power of statistical hypothesis tests .  
Subjects who are randomized but discont inue the study  may be replaced in the same cohort and 
race (Japanese or Caucasian) at the discret ion of the sponsor .  
10.2. Populations for Analyses
10.2.1. Study Participant Disposition
All subjects who discont inue from the study  will be i dentified, and the extent of their 
participat ion in the study  will be reported .  If known, a reason for their discont inuat ion will 
begiven .  
10.2.2. Study Participant Characteristics
Subjects ’age, sex, wei ght, body mass index , height, race/subcategory , or other demographic 
characterist ics will be recorded and summar ized by treatment group as well as overall.
10.3. Statistical Anal yses
Statistical analysis o f this study  will be the responsibilit y of Eli Lilly and Com pany  or 
itsdesignee .
PK analyses will be conducted for all subjects who receive at least 1 dose of LY3337641 and 
have evaluable PK data. PD analyses will be conducted on the full analysis set ,which includes 
all data from all subjects receiving at least 1 dose of LY3337641 or placebo.   Safet y analyses 
will be conducted for all randomized subjects who receive at least 1 dose of LY3337641 or 
placebo and have at least 1postdose safet y assessment ,regardless of whether they  have 
completed all  protocol  requi rements.   For QT interv al, all subjects with at least 1postdose
QTinterval measurement will be included in the analysis.
Summary  statistics, data tabulat ions, and data graphs will be provided and may be separated by  
race (Japanese and Caucasian ) as appropriate.
Addit ional exploratory  analyses of the data will be conducted as deemed appropriate.  Stu dy 
resul ts may be pool ed wi th the resul ts of other studies for populat ion PK/PDanalysis purposes.  
10.3.1. Safety Analyses
10.3.1.1. Clinical Evaluation of Safety
All IPand protocol  procedure AEs will be listed, and if the frequency o f events allows, safet y 
data will be summarized using descript ive methodol ogy.
I8K-JE-JPDB(a) Clinical Pharmacology Protoco l Page 40
LY3337641The incidence of symptoms for each treatment will be presented by  severi ty and by associ ation 
with the IPas perceived by the invest igator.  Symptoms reported to occur prior to enrollment 
will be dist inguished from those reported as new or increased in severit y during the study .  Each 
symptom  will be classified by  the m ost sui table term fro m the medical regulatory  dictionary.
The number of IP-related SAEs will be reported.
10.3.1.2. Statistical Evaluation of Safety
Safety parameters that will be assessed include lab oratory parameters, vi tal signs, and ECG 
param eters.  The param eters will  be listed and summarized using standard descriptive statist ics.  
Prior to any  stati stical analysis of QT interval , QT values will be correcte d for heart rate based on 
QTcF .  The relat ionship between concentrations o f LY3337641 and change sfrom baseline QTcF
(ΔQTcF) will be explored to assess the effect of LY3337641 concentration on the ΔQTcF.  A
detailed analysis for QT interval will be provi dedin the Statist ical Analysis Plan. Addit ional 
analysis will be performed if warranted upon review of the data.
10.3.2. Pharmacokinetic Analyses
10.3.2.1. Pharmacokinetic Parameter Estimation
PKparameter estimates for LY3337641 will be calculated by  standard noncom partmental 
methods of analysis.
In the SDcohorts, the primary parameters for analysis will be C max, area under the concentration 
versus time curve from zero to infinit y(AUC0-∞),and area under the concentration versu s time 
curve from 0 to 24 hours (AUC 0-24)of LY3337641.  In the MDcohorts, the primary  parameters 
to be calculated will include C max(orCmaxduring a dosing interval at steady state
[Cmax,ss ]) and 
area under the concentration versus time curve during the dosing interval (AUC 0-τ) of 
LY3337641 afterthe first and last dose of IP.  Other noncompart mental parameters, such as 
half-life, apparent clearance, apparent vo lume of distribut ion,and accumulat ion rati o (MD peri od 
only) ,may be reported .  
Addit ional analysis may be conducted if appropriate.
10.3.2.2. Pharmacokinetic Statistical Inference
The dose proportionalit y of selected LY 3337641 PK parameters, including log transformed C max
and relevant AUC values will be examined for all subjects and for each populat ion across the 
entire dose range using a power model approach (Smith et al. 2000) to estimate the slope of the 
power model, which represents the ratio of dose -norm alized geometr ic means.  Exploratory  
power model analysis based on the model including race and race-by-dose interacti on terms will 
also beperform ed to examine the effect of the race on dose proportionalit y.
10.3.3. Pharmacodynamic Analyses
BTK occupancy will be listed and sum marized using standard descriptive statist ics.  Addit ional 
analysis will be performed if warranted upon review of the data .
I8K-JE-JPDB(a) Clinical Pharmacology Protoco l Page 41
LY333764110.3.4. Pharmacokinetic/Pharmacodynamic Analyses
Exploratory  graphical PK/PD analyses may be conducted to evaluate the relationship between 
LY3337641 concentrations (or exposure) and PD measures.  Addit ional model -based analyses 
may be conducted if deemed appropriate.
10.3.5. Interim Analyses
The Lilly study  team  isunblinded.  Data may  be analyzed while the trial is ongoing, but no 
changes to the study  design are pl anned.  An assessment committee will not be formed .
Up to 3 interim analys es are planned to occur during the study according to the following 
timeframe : when at least safet y and PK data of (1)Day 2predose (24 hours afterfirst dose) 
beco me available fro m at least 11subjects in Cohort 1,including at least 4Caucasian subjects ; 
(2)Day 17 (48 hours afterlast dose) become available fro m Cohort 1 ; and ( 3)Day 29 beco me 
available fro m Cohort 1.   All safet y and PK data available fro m other cohorts by  this time will be 
included in the interim analysis.  The purpose of the interim analysis is to support the inclusio n 
of Japanese subjects in future studies.  T he invest igator and the Lilly clinical pharmacol ogistwill 
review the safety  and tol erabilit y data, and the PK/PD sci entist will review the PK data .  The 
investigator will remain blinded, and the Lilly study team will be unblinded during this 
interim review.
Inform ation that m ay unblind the study  during the analyses will not be reported to study  site or 
blinded personnel unt il the study has been unbl inded .
Addit ional interim analysis may be conducted at any  time throughout the study  as requi red to 
ensuresubject safety  or to help gui de dosing.
If an unplanned interim analysis is deemed necessary , the Lilly clinical pharmacologist, clinical 
research physician/invest igator, or designee will consult with the appropriate medical director or 
designee to dete rmine if it is necessary to amend the protocol.
I8K-JE-JPDB(a) Clinical Pharmacology Protoco l Page 42
LY333764111. References
Aalipour A, Advani RH. Bruton's ty rosine kinase inhibitors and their clinical potential in the 
treatm ent of B -cell malignancies : focus on ibrut inib. Ther Adv Hematol . 2014;5(4):121 -133.
Burger JA. Bruton’s ty rosine kinase (BTK) inhibitors in clinical trials. Curr Hematol Malig Rep. 
2014;9(1):44 -49.
Chakravarty  SD, Poulikakos PI, Ivashkiv LB, Salmo n JE, Kallio lias GD. Kinase inhibitors: a
new tool  for the treatm ent of  rheumatoi d arthri tis. Clin Immun ol. 2013;148(1):66 -78.
Di Paol o JA, Huang T, Bal azs M, Barbosa J, Barck KH, Bravo BJ, Carano RA, Darrow J, 
Davies DR, DeForge, LE, Diehl L, Ferrando R, Gallio n SL, Giannetti AM, Gribling P, 
Hurez V, Hymowitz SG, Jones R, Kropf JE, Lee WP, Maciejewski PM, M itchell  SA, 
Rong JH, Staker BL, Whitney  JA, Yeh S, Young WB, Yu C, Zhang J, Reif K, Currie KS. 
Specific Btk inhibit ion suppresses B cell- and myelo id cell -mediated arthrit is. Nat Chem Biol.
2011;7(1):41 -50.
Horwood NJ, Urbaniak AM, Danks L. Tec family  kinases in inflammat ion and disease. Int Rev 
Immunol . 2012;31(2):87 -103.
Smith BP, Vandenhende FR, DeSante KA, Farid NA, Welch PA, Callaghan JT, Forgue ST. 
Confidence interval criteria for assessment of dose proportionalit y. Pharm Res . 
2000;17(10):1278 -1283.
I8K-JE-JPDB(a) Clinical Pharmacology Protoco l Page 43
LY3337641Appendix 1. Abbreviations and Definitions
I8K-JE-JPDB(a) Clinical Pharmacology Protoco l Page 44
LY3337641Term Definition
AE adverse event:  Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relatio nship with this treatment.   An AE can therefore be any unfavorable and unintended 
sign (including an abnormal laboratory finding), symptom, or disease temporally associated 
with the use of a medicinal (investigational) product, whether or not related to the medicinal 
(investigation al) product.
ALP alkaline phosphatase
ALT alanine aminotransferase
AST aspartate aminotransferase
AUC area under the plasma concentration -time curve
AUC 0-∞ area under the concentration versus time curve from zero to infinity
AUC 0-24 area under the concentration versus time curve from 0 to 24 hours
AUC 0- area under the concentration versus time curve during the dosing interval
BID twice daily
blinding A procedure in which one or more parties to the trial are kept unaware of the treatment 
assignment(s).  Unless otherwise specified, blinding will remain in effect until final 
database lock.
BTK Bruton’s tyrosine kinase
Cmax maximum drug concentration
Cmax,ss maximum drug concentration during a dosing interval at steady state
complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
compliance Adherence to all the trial -related requirements, good clinical practice requirements, and the 
applicable regulatory requirements.
confirmation A process used to confirm that laboratory test results meet the quality requirements defined 
by the laboratory generating the da ta and that Lilly is confident that results are accurate.  
Confirmation will either occur immediately after initial testing or will require that samples 
be held to be retested at some defined time point, depending on the steps required to obtain 
confirmed results.
clinical research 
physicianIndividual responsible for the medical conduct of the study.  Responsibilities of the clinical 
research physician may be performed by a physician, clinical research scientist, global 
safety physician, or other medical officer.
CRU clinical research unit
I8K-JE-JPDB(a) Clinical Pharmacology Protoco l Page 45
LY3337641ECG electrocardiogram
eCRF electronic case report form
enroll The act of assigning a subject to a treatment.  Subjects who are enrolled in the trial are those 
who have been assigned to a treatment.
enter ed Subjects entered into a trial are those who sign the informed consent form directly or 
through their legally acceptable representatives.
ERB ethical review board
GCP Good Clinical Practice
HBcAb hepatitis B core antibody
HBsAg hepatitis B surface antigen
HIV human immunodeficiency virus
ICF informed consent form
informed consent A process by which a subject voluntarily confirms his or her willingness to participate in a 
particular trial, after having been informed of all aspects of the trial that are relevan t to the 
subject’s decision to participate.  Informed consent is documented by means of a written, 
signed and dated informed consent form .  
interim analysis An interim analysis is an analysis of clinical trial data, separated into treatment groups, that 
is conducted before the final reporting database is created/locked.
investigational 
product A pharmaceutical form of an active ingredient or placebo being tested or used as a reference 
in a clinical trial, including products already on the market when used or assembled 
(formulated or packaged) in a way different from the authorized form, or marketed products 
used for an unauthorized indication, or marketed products used to gain further information 
about the authorized form.
investigator A person respon sible for the conduct of the clinical trial at a trial site.  If a trial is conducted 
by a team of individuals at a trial site, the investigator is the responsible leader of the team 
and may be called the principal investigator.
IP investigational product
legal 
representativeAn individual or judicial or other body authorized under applicable law to consent, on 
behalf of a prospective subject, to the subject ’s participation in the clinical trial.
MD multiple dose
PD pharmacodynamics(s)
PK pharmacokinetic (s)
QD once daily
QTcF Fridericia -corrected QT interval
I8K-JE-JPDB(a) Clinical Pharmacology Protoco l Page 46
LY3337641RA rheumatoid arthritis
SAE serious adverse event
screen The act of determining if an individual meets minimum requirements to become part of a 
pool of potential candidates for participation in a clinical trial.   
SD single dose
SUSARs suspected unexpected serious adverse reactions 
TB tuberculosis
TBL total bilirubin level
TEAE treatment -emergent adverse event 
treatment -
emergent adverse 
eventAny untoward medical occurrence that emerges during a defined treatment period, having 
been absent pretreatment, or worsens relative to the pretreatment state , and does not 
necessarily have to have a causal relationship with this treatment
ULN upper limit of normal
I8K-JE-JPDB(a) Clinical Pharmacology Protoco l Page 47
LY3337641Appendix 2. Clinical Laboratory  Tests
Laboratory Tests a
Hematology Clinical Chemistry
Hematocrit Sodium
Hemoglobin Potassium
Erythrocy te count (RBC s) Bicarbonate
Mean cell volume Chloride 
Mean cell hemoglobin Calcium
Mean cell hemoglobin concentration Phospho rus
Leukocytes (WBC s) Magnesium
Absolute counts of: Glucose fasting
Neutrophils Blood urea nitrogen (BUN)
Lymphocy tes Uric acid
Monocytes Total cholesterol
Eosinophils Total protein
Basophils Albumin
Platelets Total bilirubin
Alkaline phosphatase (ALP)
Urinalysis Aspartate aminotransferase (AST)
Specific gravity Alanine aminotransferase (ALT)
pH Creatinine
Protein Gamma -glutamyl transferase (GGT)
Glucose CRP
Ketones Amylase
Bilirubin Lipase
Urobilinogen Ethanol testing b,c
Blood Urine drug screen b,c
Nitrite Hepatitis B surface antigen b
Hepatitis B core antibody b
Hepatitis C antibody b
HIV b
Pregnancy test d
FSH b,d
QuantiFERON ®-TBGold test b
Abbreviations:  CRP = C-reactive protein; FSH =follicle -stimulating hormone; HIV =human immunodeficiency 
virus; RBC s =red blood cells; TB=tuberculosis; WBC s =white blood cells .
aTo be performed at local laboratory .
bPerformed at screening only .  
cMay be repeated prior to admissi on to the clinical research unit .  
dTo be performed for female subjects of childbearing potential.   Serum pregnancy test at screening; u rine 
pregnancy test at all other visits .
I8K-JE-JPDB(a) Clinical Pharmacology Protoco l Page 48
LY3337641Appendix 3. Study  Governance, Regulatory  and Ethical 
Considerations
Informed Consent
Theinvest igator is responsible for:
ensuring that the subject understands the potential risks and benefits of participat ing in 
thestudy
ensuring that informed consent is given by each subject or legal representative.  This 
includes obtaining the appropriate signatures and dates on the informed consent 
form(ICF) prior to the performance o f any protocol  procedures and prior to the 
administration of IP
answering any quest ions the subject may  have throughout the study  and sharing in a 
timely  manner any  new info rmation that m ay be relevant to the subject ’swillingness to 
continue his or her participat ion in the trial
Ethical Review
The invest igator or appropriate local representative must give assurance that the ethical review 
board (ERB) was properly const ituted and convened as required by Internat ional Council for 
Harm onisat ion (ICH) guidelines and other applicable laws and regulat ions.
Docum entati on of  ERB approval  of the protocol and the ICF must be provided to Lilly  before the 
study  may begin at the investi gative si te(s).  Lilly  or its representatives must approve the ICF 
before i t is used at the invest igative site(s).  All ICFs must b e com pliant wi th the ICH gui deline 
on good clinical practice ( GCP ).
The study  site’s ERB(s) shoul d be provided wi th the f ollowing:
the current Invest igator’s Brochure and updates during the course of the study
ICF
relevant curri cula vi tae
Regulatory Considerations
This study  will be conducted in accordance wit h:
1)consensus ethics principles derived fro m internat ional ethics guidelines, 
including the Declarat ion of Helsinki and Council forInternational
Organizat ionsofMedical Sciences Internat ional Et hical Guidelines 
2)applicable ICH GCP Guidelines
3)applicable laws and regulations
Some of the obligat ions of the sponsor will be assigned to a third-party  organi zation.
I8K-JE-JPDB(a) Clinical Pharmacology Protoco l Page 49
LY3337641Protocol Signatures
The sponsor’s responsible medical o fficer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately  describes the pl anned design and conduct of 
thestudy .  
After reading the protocol, each principal invest igator will sign the protocol signature page and 
send a copy  of the sig ned page to a Lilly representative.
Final Report Signature
The invest igator or designee will sign the clinical study report for this study, indicat ing 
agreem ent wi th the analyses, results, and conclusio ns of the report.
The sponsor’s responsible medical o fficer and statistician will sign/approve the final clinical 
study  report for this study , confirming that, to the best of his or her knowledge, the report 
accurately describes the conduct and results of the study .
Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly  or its representatives will do the fo llowing:
provi de instructi onal materi al to the study  sites, as appropriate
provi de training to i nstruct the invest igators and study  coordinators.  This training will 
give instruction on the protocol, the complet ion of the electronic case report forms , and 
study  procedures
make periodic visit s to the study  site
be available for co nsultation and stay in contact with the study site personnel by mail, 
telephone, and/or fax
review and evaluate electronic case report form data and/or use standard computer edits 
to detect errors in data collect ion
conduct a qualit y review of the database
In addit ion, Lilly or its representatives will periodically check a sample of the subject data 
recorded against source documents at the study  site.  The study  may be audi ted by  Lilly and/or 
regul atory  agencies at any  time.  Invest igators will be given not ice before an audit occurs.
The invest igator will keep records of all original source data.  This might include laboratory 
tests, m edical records, and clinical notes.  If requested, the invest igator will provide the sponsor, 
applicable regulatory  agencies, and applicable ERBs with direct access to the original 
source documents.
I8K-JE-JPDB(a) Clinical Pharmacology Protoco l Page 50
LY3337641Data Collection Tools/Source Data
An electronic data capture sy stem  will be used in this study .  The si te must define and retain all 
source records and must maintain a record of any  data where source data are directly entered into 
the data capture system.
Study and Site Closure
Discontinuation of Study Sites
Study  site parti cipat ion may be discont inued if Lilly , the invest igator, or the ERB of the study  
sitejudges it necessary for medical, safety , regul atory , or other reasons consistent with 
applicable laws, regulat ions, and GCP.
Discontinuation of the Study
The study  will be di scontinued if Lilly judges it necessary for medical, safet y, regul atory , or 
other reasons consistent with ap plicable l aws, regulat ions, and GCP.
I8K-JE-JPDB(a) Clinical Pharmacology Protoco l Page 51
LY3337641Appendix 4. Hepatic Monitoring Tests for Treatment -
Emergent A bnormality
Selected tests m ay be obtained in the event of a treatment -emergent hepatic abnormalit y and may  
be required in fo llow-up wi th subjects in consultation with theLilly  clinical pharmaco logist.
Hepatic Monitoring Tests
Hepatic Hematology a Haptoglobin a
Hemoglobin
Hematocrit Hepatic Coagulation a
RBC s Prothrombin time
WBC s Prothrombin time, INR
Neutrophils, segmented
Lymphocy tes Hepatic Serologies a,b
Monocytes Hepatitis A antibody, total
Eosinophils Hepatitis A antibody, IgM
Basophils Hepatitis B surface antigen
Platelets Hepatitis B surface antibody
Hepatitis B core antibody
Hepatic Chemistry a Hepatitis C antibody
Total bilirubin Hepatitis E antibody, IgG
Conjugated bilirubin Hepatitis E antibody, IgM
Alkaline phosphatase
ALT Anti -nuclear antibody a
AST
GGT
CPK Anti ‒smooth muscle antibody (or anti -actin 
antibody) a
Abbreviations:  ALT =alanine aminotransferase; AST =aspartate aminotransferase; CPK =creatinine 
phosphokinase; GGT =gamma -glutamyl transferase; Ig =immunoglobulin; INR =internatio nal normalized
ratio; RBC s =red blood cells; WBCs = white blood cells.
aAssay ed by Lilly -designated or local laboratory.
bReflex/co nfirmation dependent on regulatory requirements and/or testing availability .
I8K-JE-JPDB(a) Clinical Pharmacology Protoco l Page 52
LY3337641Appendix 5. Blood Sampling Summary
This table summarizes the approximate number of venipunctures and blood volumes for all 
blood sam pling (screening, safet y laboratori es, and bioanaly tical assays) during the study .  
Fewer venipunctures and blood draws may actually  occur, but t his will not require a 
protocol amendment.
Protocol I8K-JE-JPDB Sampling Summary for Cohort s1 and 5
PurposeMaximum Blood Volume 
per Sample (mL)Maximum Number 
of Blood SamplesMaximum Total 
Volume (mL)
Screening tests a 45 1 45
Clinical laboratory tests a 12 5 60
Pharmacokinetics 2 33 66
Pharmacodynamics (BTK 
occupancy)16 18 288
Pharmacogenetics 10 1 10
Non-PGx stored sample 9.5 3 28.5
Total 497.5
Total for clinical purposes [rounded up to nearest 10 mL] 500
Abbreviations :  BTK =Bruton’s tyrosine kinase; PGx =pharmacogenomics.
aAdditional samples may be drawn if needed for safety purposes.
Protocol I8K -JE-JPDB Sampling Summary for Cohort s 2, 3, and 4
PurposeMaximum Blood Volume 
per Sample (mL)Maximum Number 
of Blood SamplesMaximum Total 
Volume (mL)
Screening tests a 45 1 45
Clinical laboratory tests a 12 3 36
Pharmacokinetics 2 16 32
Pharmacodynamics (BTK 
occupancy)16 9 144
Pharmacogenetics 10 1 10
Non-PGx stored sample 9.5 3 28.5
Total 295.5
Total for clinical purposes [rounded up to nearest 10 mL] 300
Abbreviations :  BTK =Bruton’s tyrosine kinase; PGx =pharmacogenomics.
aAdditional samples may be drawn if needed for safety purposes.
I8K-JE-JPDB(a) Clinical Pharmacology Protoco l Page 53
LY3337641Appendix 6. Protocol I8K-JE-JPDB Blinding/Unblinding 
Plan
Levels of unblinding are indicated in the table belo w.  Thi s table provi des general  guidance as to 
who will be allowed access to rando mizat ion codes at various steps of the trial.  The inf ormation 
in the protocol will always take precedence over this table.  For interim analysis, appropriate 
interim analysis team members, including statist ician, programmer, and data manager will be 
ident ified and agreed upon between Lilly and the third -party organi zation.  
Randomization data are kept strict ly confident ial and are accessible only by  authori zed personnel 
until unblinding of the trial as described below.  All measures possible must be taken to maintain 
the blind, which means that access to ran domizat ion code smust be restricted to authorized 
personnel as described in the protocol and summarized in the table below.
I8K-JE-JPDB(a) Clinical Pharmacology Protoco l Page 54
LY3337641Protocol I8K-JE-JPDB Blinding and Unblinding Plan
Study Timelines
Study Team Member Screening RandomizationTreatment 
Phase Follow -UpDatabase 
Lock
General
Drug Supply NA U U U U
Randomization Statisticians NA U U U U
ECG Reader NA B B B B
BioanalysisLab/Sample Analysis NA U U U U
Clinical Site
Pharmacist NA U U U U
Dosing Nurse NA U U U U
Subject NA B B B B
Investigator NA B B B B
Study Monitor NA U U U U
Covance/CDARO
Project Integration NA U U U U
Data Management NA U U U U
Programming NA U U U U
Statistician NA U U U U
Medical Writing NA U U U U
Pharmacokinetic Scientist/Associate NA U U U U
Lilly
Biopharm Coordinato r NA U U U U
CPA NA U U U U
DSA NA U U U U
SDTM Core Team NA U U U U
Statistician NA U U U U
Medical Writing NA U U U U
CP NA U U U U
Pharmacokinetic Scientist/Associate NA U U U U
Medical Writing NA U U U U
Abbreviations:  B =blinded; CP =clinical pharmacologist; CPA =clinical pharmacology associate; DSA =data 
sciences associate; ECG =electrocardiogram; SDTM =study data tabulation model; U =unblinded.
I8K-JE-JPDB(a) Clinical Pharmacology Protoco l Page 55
LY3337641Appendix 7. Protocol A mendment I8K-JE-JPDB (a) 
Summary
A Single -and Multiple -Dose Study  to Evaluate the Safety , 
Tolerability , Pharmacokinetics, and Pharmacody namics 
of LY3337641 in Japanese and Caucasian Healthy  
Subjects
Overview
Protocol  I8K-JE-JPDB , A Single -and Mult iple-Dose Study  to Eval uate the Safet y, Tolerabilit y, 
Pharmacokinet ics, and Pharmacodynamics of LY3337641 in Japanese and Caucasian Healt hy 
Subjects, has been amended.  The new protocol is indicated by Amendment ( a) and will be used 
to conduct the study  in place o f any preceding versio n of the protocol .
The overall changes and rationale for the changes made to this protocol are as fo llows:
Addit ion of “Review preexist ing condit ions/AEs” and “Review concomitant 
medicat ions” to the Days 17, 22, 25, and 29/EoS for Cohorts 1 and 5 and to the Day s 3,8, 
11, and 15/EoS for the Cohorts 2, 3, and 4 in the table of Schedule of Act ivities as these 
assessments are re quired for all visits.
Clarified that on Day  15 in Cohort 5, only the morning dose will be administered for 
twice-daily  regimen in the footnote of the Schedule of Act ivities.
Addit ion of the exempt ion criteria for a chest x -ray at screening.
Addit ion of subject’s race criteria and the definit ion of 1stgenerati on Japanese.
I8K-JE-JPDB(a) Clinical Pharmacology Protoco l Page 56
LY3337641The overall changes and rationale for the changes made to this protocol are described in the 
following table :
Table JPDB .3. Amendment Summary for Protocol I8K-JE-JPDB Amendment(a)
Section # and Name Descriptio nof Change Brief Rationale
2. Schedule of Activities Addition of “Review preexisting 
conditio ns/AEs” and “Review concomitant 
medications” to the Days 17, 22, 25, and 
29/EoS for Cohorts 1 and 5 and to the 
Days 3, 8, 11, and 15/EoS for the Cohorts 
2, 3, and 4 in the table of Schedule of 
Activities.Both “Review preexisting 
conditio ns/AEs ”and “Review 
concomitant medications ”are required 
for all visits throughout the study , but 
were inadvertently missing for the visits .
2. Schedule of Activities Clarified that on Day 15 in Cohort 5, only 
the mo rning dose will be administered for 
twice -daily  regimen in the footnote of the 
Schedule of Activit ies.The correct textis written in the section 
7.2.1. Selection and Timing of Doses. 
However, to resolve the inconsist ency 
between the 2 sections, the footnote was 
corrected.
6. Study Population Addition of the exemption criteria for a 
chest x -ray at screening.This sentence was added to avoid 
unnecessary x-ray s.
6.1. Inclusion Criteria Addition of subject’s race criteria and the 
definition of 1stgeneration Japanese.This criterion was inadvertently missing 
and has been added t o ensure quality of 
study data by recruit ingthe intended 
race groups to the study.
I8K-JE-JPDB(a) Clinical Pharmacology Protocol Page 57
LY3337641Revised Protocol Sections
Note: All deletions have been ident ified by strikethroughs .
All additions have been ident ified by the use of underscore .
2. Schedule of A ctivities
Study Schedule Protocol I8K -JE-JPDB (Cohorts 1 and 5)
Visit Follow -Upa
Study Day 16 17 19 22 25 29/
EoS
Review preexisting 
conditio ns/AE sdX X X X X X
Review concomitant 
medication sdX X X X X X
cSubjects will be dosed ever y day from Day  1 through Day 15.  For twice -daily  regimen, only the morning dose 
will be administered on Day 15 dose will be administered in the morning only .
Study Schedule Protocol I8K -JE-JPDB (Cohorts 2, 3, and 4)
Visit Follow -Upa
Study Day 2 3 5 8 11 15/EoS
Review preexisting 
conditio ns/AE sX X X X X X
Review concomitant 
medication sX X X X X X
6. Study  Population
Eligibilit y of subjects for study  enrollment will be based on the results of screening medical 
history , physical  examinat ion, vital signs, clinical laboratory tests, and ECG.  
A chest x -ray will becompleted at screening unless one has been obtained within the past 
12months, and the x -ray and/or report are available for review.
6.1. Inclusion Criteria
[37] are 1stgenerati onJapanese or Caucasian.
To qualify  as a subject of 1stgenerat ion Japanese origin, the subject, the 
subject’s bio logical parents, and all o f the subject’s bio logical  grandparents 
must be of exclusive Japanese descent and born in Japan.
PPDLeo Document ID = 722f39a5-0f6a-47dd-9bd4-1c4fe6829144
Approver: 
Approval Date & Time: 16-Mar-2017 08:35:40 GMT
Signature meaning: Approved
Approver: 
Approval Date & Time: 16-Mar-2017 19:18:38 GMT
Signature meaning: ApprovedPPD